CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – *2020 EXECUTIVE SUMMARY*

Alan J. Garber, MD, PhD, MACE[1]; Yehuda Handelsman, MD, FACP, FNLA, MACE[2];
George Grunberger, MD, FACP, FACE[3]; Daniel Einhorn, MD, FACP, FACE[4];
Martin J. Abrahamson, MD[5]; Joshua I. Barzilay, MD, FACE[6]; Lawrence Blonde, MD, FACP, MACE[7];
Michael A. Bush, MD, FACE[8]; Ralph A. DeFronzo, MD[9]; Jeffrey R. Garber, MD, FACP, FACE[10];
W. Timothy Garvey, MD, FACE[11]; Irl B. Hirsch, MD[12]; Paul S. Jellinger, MD, MACE[13];
Janet B. McGill, MD, FACE[14]; Jeffrey I. Mechanick, MD, FACN, FACP, MACE, ECNU[15];
Leigh Perreault, MD[16]; Paul D. Rosenblit, MD, PhD, FNLA, FACE[17];
Susan Samson, MD, PhD, FRCPX, FACE[18]; Guillermo E. Umpierrez, MD, FACP, FACE[19]

This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician.

Abbreviations:

A1C = hemoglobin A1C; **AACE** = American Association of Clinical Endocrinologists; **ABCD** = adiposity-based chronic disease; **ACCORD** = Action to Control Cardiovascular Risk in Diabetes; **ACCORD BP** = Action to Control Cardiovascular Risk in Diabetes Blood Pressure; **ACE** = American College of Endocrinology; **ACEI** = angiotensin-converting enzyme inhibitor; **AGI** = alpha-glucosidase inhibitor; **apo B** = apolipoprotein B; **ARB** = angiotensin II receptor blocker; **ASCVD** = atherosclerotic cardiovascular disease; **BAS** = bile acid sequestrant; **BMI** = body mass index; **BP** = blood pressure; **CCB** = calcium channel blocker; **CGM** = continuous glucose monitoring; **CHD** = coronary heart disease; **CKD** = chronic kidney disease; **DKA** = diabetic ketoacidosis; **DPP4** = dipeptidyl peptidase 4; **eGFR** = estimated glomerular filtration rate; **EPA** = eicosapentaenoic acid; **ER** = extended release; **FDA** = Food and Drug Administration; **GLP1** = glucagon-like peptide 1; **HDL-C** = high-density-lipoprotein cholesterol; **HeFH** = heterozygous familial hypercholesterolemia; **LDL-C** = low-density-lipoprotein cholesterol; **LDL-P** = low-density-lipoprotein particle; **Look AHEAD** = Look Action for Health in Diabetes; **NPH** = neutral protamine Hagedorn; **OSA** = obstructive sleep apnea; **PCSK9** = proprotein convertase subtilisin-kexin type 9 serine protease; **RCT** = randomized controlled trial; **SU** = sulfonylurea; **SGLT2** = sodium-glucose cotransporter 2; **SMBG** = self-monitoring of blood glucose; **T2D** = type 2 diabetes; **TZD** = thiazolidinedione

EXECUTIVE SUMMARY

This algorithm for the comprehensive management of persons with type 2 diabetes (T2D) was developed to provide clinicians with a practical guide that considers the whole patient, his or her spectrum of risks and complications, and evidence-based approaches to treatment. It is now clear that the progressive pancreatic beta-cell defect that drives the deterioration of metabolic control over time begins early and may be present before the diagnosis of T2D (1-3). In addition to advocating glycemic control to reduce microvascular complications, this document highlights obesity and prediabetes as underlying risk factors for the development of T2D and associated macrovascular complications. In addition, the algorithm provides recommendations for blood pressure (BP) and lipid control, the two most important risk factors for atherosclerotic cardiovascular disease (ASCVD).

Since originally drafted in 2013, the algorithm has been updated as new therapies, management approaches, and important clinical data have emerged. The current algorithm includes up-to-date sections on lifestyle therapy and all classes of obesity, antihyperglycemic, lipid-lowering, and antihypertensive medications approved by the U.S. Food and Drug Administration (FDA) through December 2019. In addition, the algorithm is formulated to be consistent with American Association of Clinical Endocrinologists (AACE) position statements on adiposity- and dysglycemia-based chronic disease models for early and sustainable preventive care (4,5).

This algorithm supplements the AACE and American College of Endocrinology (ACE) 2015 Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan (6) and is organized into discrete sections that address the following topics: the founding principles of the algorithm, lifestyle therapy, obesity, prediabetes, management of hypertension and dyslipidemia, and glucose control with noninsulin antihyperglycemic agents and insulin. In the accompanying algorithm, a chart summarizing the attributes of each antihyperglycemic class appears at the end.

Principles

The founding principles of the Comprehensive Type 2 Diabetes Management Algorithm are as follows (see Comprehensive Type 2 Diabetes Management Algorithm—Principles):

1. Lifestyle optimization is essential for all patients with diabetes. Lifestyle optimization is multifaceted, ongoing, and should engage the entire diabetes team. However, such efforts should not delay needed pharmacotherapy in higher risk individuals, which can be initiated and continued simultaneously and adjusted based on patient response to lifestyle efforts. The need for concurrent medical therapy should not be interpreted as a failure of lifestyle management but as an adjunctive intervention.

2. Minimizing the risk of both severe and nonsevere hypoglycemia is a priority.

3. Minimizing risk of weight gain and abnormal adiposity and promoting weight loss in those patients with adiposity-based chronic disease (ABCD; the medical diagnostic term for overweight/obesity), are high priorities for long-term health. Given its ability to prevent progression to diabetes and promote a favorable therapeutic profile in diabetes, weight loss should be strongly considered in all patients with prediabetes and T2D who also have ABCD. Weight-loss therapy should consist of a specific lifestyle prescription that includes a reduced-calorie healthy meal plan, physical activity, and behavioral interventions. Weight-loss medications approved for the chronic management of obesity should also be considered if needed to obtain the degree of weight loss required to achieve therapeutic goals in prediabetes and T2D. ABCD is a chronic disease, and a long-term commitment to therapy is

necessary. Early intervention to prevent progression to T2D in people with prediabetes and/or abnormal adiposity with insulin resistance is important because later intervention to manage T2D and its complications is generally more expensive and carries greater risks.

4. The hemoglobin A1c (A1C) target should be individualized based on numerous factors, such as age, life expectancy, comorbid conditions, duration of diabetes, risk of hypoglycemia or adverse consequences from hypoglycemia, patient motivation, and adherence. Glycemic control targets include fasting and postprandial glucose as determined by self-monitoring of blood glucose (SMBG). In recent years, continuous glucose monitoring (CGM) has become more available to people with T2D and has added a considerable clarity to patients' and clinicians' understanding of glycemic patterns.

5. An A1C level of ≤6.5% (48 mmol/mol) is considered optimal if it can be achieved in a safe and affordable manner, but higher targets may be appropriate for certain individuals and may change for a given individual over time.

6. The choice of diabetes therapies must be individualized based on attributes specific to both patients and the medications themselves. Medication attributes that affect this choice include initial A1C, duration of T2D, and obesity status. Other considerations include antihyperglycemic efficacy; mechanism of action; risk of inducing hypoglycemia; risk of weight gain; other adverse effects; tolerability; ease of use; likely adherence; cost; and safety or risk reduction in heart, kidney, or liver disease.

7. The choice of therapy depends on the patient's cardiac, cerebrovascular, and renal status. Combination therapy is usually required and should involve agents with complementary mechanisms of action.

8. Comorbidities must be managed for comprehensive care, including management of lipid and BP abnormalities with appropriate therapies and treatment of other related conditions.

9. Targets should be achieved as soon as possible. Therapy must be evaluated frequently (e.g., every 3 months) until stable using multiple criteria, including A1C, SMBG records (fasting and postprandial) or CGM tracings, documented and suspected hypoglycemia events, lipid and BP values, adverse events (weight gain, fluid retention, hepatic or renal impairment, or ASCVD), comorbidities, other relevant laboratory data, concomitant drug administration, complications of diabetes, and psychosocial factors affecting patient care. With CGM, initial therapy adjustments can be made much more frequently until stable. Less frequent monitoring is acceptable once targets are achieved.

10. The choice of therapy includes ease of use and affordability. The therapeutic regimen should be as simple as possible to optimize adherence. The initial acquisition cost of medications is only a part of the total cost of care, which includes monitoring requirements, risks of hypoglycemia and weight gain, and future complication management. Safety and efficacy should be given a higher priority than medication acquisition cost alone.

11. AACE/ACE recommends using CGM whenever indicated to assist patients in reaching glycemic goals safely. Professional CGM is useful to clinicians wishing to personalize patients' management plans or assess effectiveness of therapy.

12. This algorithm includes every FDA-approved class of medications for T2D (as of December 2019).

Lifestyle Therapy

The key components of lifestyle therapy include medical nutrition therapy and healthy eating patterns, regular and adequate physical activity, sufficient amounts of sleep, behavioral support, and smoking cessation with avoidance of all tobacco products (see Comprehensive Type 2 Diabetes Management Algorithm—Lifestyle Therapy). In the algorithm, recommendations appearing on the left apply to all patients. Patients with increasing burden of obesity or related comorbidities may also require the additional interventions listed in the middle and right columns of the Lifestyle Therapy algorithm panel.

Lifestyle therapy begins with motivational interviewing techniques, nutrition counseling, and education. All patients should strive to attain and maintain an optimal weight through a primarily plant-based meal plan high in polyunsaturated and monounsaturated fatty acids, with limited intake of saturated fatty acids and avoidance of *trans* fats. Patients with overweight (body mass index [BMI] 25 to 29.9 kg/m^2 or appropriate ethnicity-adjusted ranges) or obesity (BMI ≥30 kg/m^2 or appropriate ethnicity-adjusted ranges; see ABCD/Obesity section) should also restrict their caloric intake with the initial goal of reducing body weight by at least 5 to 10% (or more as needed to ameliorate obesity-related complications) and then targeting appropriate long-term goals for optimal or normal range anthropometrics. As shown in the Look AHEAD (Action for Health in Diabetes) and Diabetes Prevention Program studies, lowering caloric intake is the main driver for weight loss (7-10). The clinician, a registered dietitian, or a nutritionist (i.e., a healthcare professional with formal training in the nutritional needs of people with diabetes) should discuss recommendations in plain language at the initial visit and, at least briefly, with each follow-up office visit. Discussion should focus on foods that promote health, including information on specific foods, meal planning, grocery shopping, and dining-out strategies. Patients should be instructed on proper interpretation of Nutrition

Facts Labels on packaged foods. Clinicians should be sensitive to patients' ethnic and cultural backgrounds and their associated food preferences (11). In addition, education on medical nutrition therapy for patients with diabetes should also address the need for consistency in day-to-day carbohydrate intake; limiting sucrose-containing, high fructose-containing, or other high-glycemic-index foods; as well as the importance of eating a healthy, high-fiber breakfast, and not skipping meals, to lessen the risk of unhealthy eating late at night. Those who require short-acting insulin with meals need to learn how to adjust insulin doses to match carbohydrate intake (e.g., use of carbohydrate counting with glucose monitoring) (6,12). A simplified bolus insulin dosage algorithm based on premeal and bedtime glucose patterns can also be effective (13). Structured counseling (e.g., weekly or monthly sessions with a specific weight-loss curriculum) and diabetes-specific meal replacement programs have been shown to be more effective than standard in-office counseling (7,10,14-21). Additional nutrition recommendations can be found in the 2013 Clinical Practice Guidelines for Healthy Eating for the Prevention and Treatment of Metabolic and Endocrine Diseases in Adults from AACE/ACE and The Obesity Society (22).

After nutrition, physical activity is the main component in weight loss and maintenance programs. Regular physical activity—both aerobic exercise and strength training—improves glucose control, lipid levels, and BP; decreases the risk of falls and fractures; and improves functional capacity and sense of well-being (23-30). In Look AHEAD, which had a weekly goal of ≥175 minutes of moderately intense activity, minutes of physical activity were significantly associated with weight loss, suggesting that those who were more active lost more weight (7). The physical activity regimen should involve ≥150 minutes per week of moderate-intensity activity such as brisk walking (e.g., 15- to 20-minute miles) and strength training. Patients should start any new activity slowly and gradually increase intensity and duration as they become accustomed to the exercise. Structured programs can help patients learn proper technique, establish goals, prevent injury, and stay motivated. Wearable technologies such as pedometers or accelerometers can provide valuable information to motivate as well as guide healthy amounts of physical activity. Patients with diabetes and/or severe obesity or complications should be evaluated for contraindications and/or limitations to increased physical activity, and a physical activity prescription should be developed for each patient according to both goals and limitations. More detail on the benefits and risks of physical activity and the practical aspects of implementing a training program in people with T2D can be found in a joint position statement from the American College of Sports Medicine and American Diabetes Association (31).

Adequate rest is important for maintaining energy levels and well-being, and all patients should be advised to sleep on average approximately 7 hours per night. Evidence supports an association of 6 to 9 hours of sleep per night with a reduction in cardiometabolic risk factors, whereas sleep deprivation aggravates insulin resistance, hypertension, hyperglycemia, and dyslipidemia and increases inflammatory cytokines (32-37). Daytime drowsiness, a frequent symptom of sleep disorders such as sleep apnea, is associated with increased risk of accidents, errors in judgment, and diminished performance (38). Basic sleep hygiene recommendations should be provided to all patients with diabetes. The most common type of sleep apnea, obstructive sleep apnea (OSA), is caused by physical obstruction of the airway during sleep. The resulting lack of oxygen causes the patient to awaken and snore, snort, and grunt throughout the night. The awakenings may happen hundreds of times per night, often without the patient's awareness. OSA is more common in males, the elderly, and persons with obesity (39,40). People with suspected OSA should be referred for a home study in lower-risk settings or to a sleep specialist for formal evaluation and treatment in higher-risk settings (6).

Behavioral support for lifestyle therapy includes the structured weight loss and physical activity programs mentioned above as well as support from family and friends. Patients should be encouraged to join community groups dedicated to a healthy lifestyle for emotional support and motivation. In addition, obesity and diabetes are associated with high rates of anxiety and depression, which can adversely affect outcomes (41,42). Alcohol and substance abuse counseling should be provided where appropriate. Healthcare professionals should assess patients' mood and psychological well-being and refer patients with mood disorders to mental healthcare professionals. A recent meta-analysis of psychosocial interventions provides insight into successful approaches, such as cognitive behavior therapy (43).

Smoking cessation is the final, and perhaps most important, component of lifestyle therapy and involves avoidance of all tobacco products. Nicotine replacement therapy and other pharmacologic interventions (e.g., sustained-release bupropion and varenicline) should be considered in patients having difficulty with smoking cessation. Structured programs should be recommended for patients unable to stop smoking on their own (6).

Obesity

ABCD has been advocated by AACE as a new diagnostic term that better defines obesity as a disease (4), and this term has been endorsed by the European Association for the Study of Obesity (44). The disease is adiposity-based because it involves abnormalities in the mass distribution and function of adipose tissue. It is a chronic disease because it is life-long; associated with complications that confer morbidity and mortality; and has a natural history that offers opportunities for primary, secondary, and tertia-

ry prevention and treatment (4,45,46). An evidence-based approach to the treatment of ABCD incorporates lifestyle, medical, and surgical options; balances risks and benefits; and emphasizes medical outcomes that address the complications of obesity. Weight loss should be considered in all patients with ABCD who have prediabetes or T2D, given the known therapeutic effects of weight loss to lower glycemia, improve the lipid profile, and reduce BP in all patients with glucose abnormalities and prevent or delay the progression to T2D in patients with prediabetes (6,45,47). Weight loss also improves other common complications in patients with ABCD, including nonalcoholic fatty liver disease and obstructive sleep apnea, and decreases mechanical strain on the lower extremities (hips and knees), as documented in the AACE obesity guidelines (47).

The AACE Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity and Treatment Algorithm (47) provide evidence-based recommendations for obesity care including screening, diagnosis, clinical evaluation and disease staging, therapeutic decision-making, and follow-up. This Algorithm should be applied to the treatment of patients with obesity with the goal of preventing progression to prediabetes and/or T2D. Rather than a BMI-centric approach for the treatment of patients who have overweight or obesity, the AACE has emphasized a complications-centric model (see Comprehensive Type 2 Diabetes Management Algorithm—Complications-Centric Model for Care of the Patient with Overweight/Obesity). This approach incorporates 3 disease stages: Stage 0 (elevated BMI with no obesity complications), Stage 1 (accompanied by one or more mild to moderate obesity complication), and Stage 2 (the presence of ≥1 severe complication) (47,48). The patients who will benefit most from medical and surgical intervention have obesity-related complications that can be classified into 2 general categories: insulin resistance/cardiometabolic disease (e.g., cardiovascular disease or diabetes) and biomechanical consequences of excess body weight (e.g., osteoarthritis or sleep apnea; see AACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity) (47,49). Clinicians should evaluate patients for the risk, presence, and severity of complications, regardless of BMI, and these factors should guide treatment planning and further evaluation (50,51). Once these factors are assessed, clinicians can set therapeutic goals and select appropriate types and intensities of treatment that may help patients achieve their weight-loss goals linked to the prevention or amelioration of weight-related complications. The primary clinical goal of weight-loss therapy in patients with prediabetes is to prevent progression to T2D. In patients with T2D, weight loss has an extremely favorable therapeutic profile that includes improved glycemic control with less need for diabetes medications; achievement of diabetes remission in some patients; and improve-

ments in blood pressure, lipids, hepatic steatosis, OSA, osteoarthritis, renal function, mobility, pain, and quality of life (47,52). Patients should be periodically reassessed to determine if targets for improvement have been reached; if not, weight-loss therapy should be changed or intensified. Lifestyle therapy can be recommended for all patients with ABCD, and more intensive options can be prescribed for patients with complications, such as diabetes or prediabetes, consistent with the complications-centric approach in the AACE obesity guidelines (47). For example, weight-loss medications can be used to intensify therapy in combination with lifestyle therapy for all patients with a BMI ≥27 kg/m^2 having complications and for patients with BMI ≥30 kg/m^2 whether or not complications are present. The FDA has approved 8 drugs as adjuncts to lifestyle therapy in patients with overweight or obesity. Diethylproprion, phendimetrazine, and phentermine may be used for short-term (≤3 months) weight-reduction therapy, whereas orlistat, phentermine/topiramate extended release (ER), lorcaserin, naltrexone ER/bupropion ER, and liraglutide 3 mg have been approved for long-term weight-reduction therapy. Obesity medications predictably induce greater weight loss than that achieved by lifestyle interventions alone and maintain weight loss for a greater duration of time (47). In clinical trials, the 5 drugs approved for long-term use were associated with statistically significant weight loss (placebo-adjusted decreases ranged from 2.9% with orlistat to 9.7% with phentermine/topiramate ER) after 1 year of treatment. These agents can improve BP and lipids, prevent progression to diabetes, and improve glycemic control and lipids in patients with T2D (53-70). Bariatric surgery should be considered for adult patients with a BMI ≥35 kg/m^2 and comorbidities, especially if therapeutic goals have not been reached using other modalities (6,71). A successful outcome of surgery usually requires a long-term outpatient commitment to follow-up and support (71).

Prediabetes

Prediabetes reflects failing pancreatic islet beta-cell compensation for an underlying state of insulin resistance, most commonly caused by excess body weight or obesity. Current criteria for the diagnosis of prediabetes include impaired glucose tolerance, impaired fasting glucose, or insulin resistance (metabolic) syndrome (see Comprehensive Type 2 Diabetes Management Algorithm—Prediabetes Algorithm). These factors are associated with a 5-fold increase in future T2D (5,72).

The primary goal of prediabetes management is weight loss in patients with overweight or obesity. Whether achieved through lifestyle therapy alone or a combination of lifestyle therapy with pharmacotherapy and/or surgery, weight loss reduces insulin resistance and can effectively prevent progression to diabetes as well as improve plasma lipid profile and BP (54,58,59,61,63,70,73). The combi-

nation of lifestyle intervention and obesity medications can be highly effective as demonstrated in clinical trials with phentermine/topiramate ER (59) and liraglutide 3 mg (74), for example, which reduced progression to diabetes by ~80% over the 2- to 3-year course of these studies. When indicated, bariatric surgery can be highly effective in preventing progression from prediabetes to T2D (72). However, weight may not directly address the pathogenesis of declining beta-cell function, and patients can remain at increased risk of future diabetes.

For patients with glucose intolerance that persists despite lifestyle change and weight loss approaches, antihyperglycemic medications such as metformin and acarbose also reduce the risk of future diabetes in patients with prediabetes by 25 to 30%. Both medications are relatively well-tolerated and safe, and they may confer a cardiovascular risk benefit (73,75-77). In clinical trials, insulin sensitizers (thiazolidinediones [TZDs]) prevented future development of diabetes in 60 to 75% of subjects with prediabetes (78-80). Cardiovascular benefits of TZDs, such as reduced major adverse cardiovascular events, have been documented in T2D and in patients with prediabetes and a history of stroke (81,82). However, TZDs have been associated with adverse outcomes, including weight gain related to subcutaneous fat increases (despite visceral adiposity reduction), water retention, and heart failure in susceptible patients, such as those with pre-existing ventricular dysfunction. In addition, there is a small increased risk of distal limb bone fractures (78-80). No medications (either weight-loss drugs or antihyperglycemic agents) are approved by the FDA solely for the management of prediabetes and/or prevention of T2D.

As with diabetes, prediabetes and metabolic syndrome represent states of accelerated atherosclerosis and increased risk for ASCVD. Patients with prediabetes should be offered lifestyle therapy and pharmacotherapy to achieve lipid and BP targets that will reduce ASCVD risk.

Blood Pressure

Elevated BP in patients with T2D is associated with an increased risk of cardiovascular events (see Comprehensive Type 2 Diabetes Management Algorithm—ASCVD Risk Factor Modifications Algorithm). The AACE recommends that BP control be individualized, but that a target of <130/80 mm Hg is appropriate for most patients. Less-stringent goals may be considered for frail patients with complicated comorbidities or those who have adverse medication effects, whereas a more intensive goal (e.g., <120/80 mm Hg) should be considered for some patients if this target can be reached safely without adverse effects from medication. Lower BP targets have been shown to be beneficial for patients at high risk for stroke (83-85). Among participants in the ACCORD-BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure) trial, there were no significant differences in primary

cardiovascular outcomes or all-cause mortality between standard therapy (which achieved a mean BP of 133/71 mm Hg) and intensive therapy (mean BP of 119/64 mm Hg). Intensive therapy did produce a comparatively significant reduction in stroke and microalbuminuria, but these reductions came at the cost of requiring more antihypertensive medications and produced a significantly higher number of serious adverse events. In particular, a greater likelihood of decline in renal function was observed in the intensive arm of ACCORD-BP (86). A meta-analysis of antihypertensive therapy in patients with T2D or impaired fasting glucose demonstrated similar findings. Systolic BP ≤135 mm Hg was associated with decreased nephropathy and a significant reduction in all-cause mortality compared with systolic BP ≤140 mm Hg. Below 130 mm Hg, stroke and nephropathy, but not cardiac events, declined further, but serious adverse events increased by 40% (83).

Lifestyle therapy can help T2D patients reach their BP goal:

- Weight loss can improve BP in patients with T2D. Compared with standard intervention, the results of the Look AHEAD trial found that significant weight loss is associated with significant reduction in BP without the need for increased use of antihypertensive medications (8).
- Sodium restriction is recommended for all patients with hypertension. Clinical trials indicate that potassium chloride supplementation is associated with BP reduction in people without diabetes (87). The Dietary Approaches to Stop Hypertension (DASH) meal plan, which is low in sodium and high in dietary potassium, can be recommended for all patients with T2D without renal insufficiency (88-93).
- Numerous studies have shown that moderate alcohol intake is associated with a lower incidence of heart disease and cardiovascular mortality (94,95).
- The effect of physical activity in lowering BP in people without diabetes has been well-established. In hypertensive patients with T2D, however, physical activity appears to have a more modest effect (31,96); nevertheless, it is reasonable to recommend a regimen of moderately intense physical activity in this population.

Most patients with T2D and hypertension will require medications to achieve their BP goal. Angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), beta blockers, calcium channel blockers (CCBs), and thiazide diuretics are favored choices for first-line treatment (97-101). The selection of medications should be based on factors such as the presence of albuminuria, ASCVD, heart failure, or post–myocardial infarction status as well as patient race/ethnicity, possible metabolic side effects, pill burden, and cost. Because ACEIs and ARBs can slow progression of nephropathy and retinopathy, they are preferred for patients with T2D

(98,102-104). Patients with heart failure could benefit from beta blockers, those with prostatism from alpha blockers, and those with coronary artery disease from beta blockers or CCBs. In patients with BP >150/100 mm Hg, two agents should be given initially because it is unlikely any single agent would be sufficient to achieve the BP target. An ARB-ACEI combination more than doubles the risk of renal failure and hyperkalemia and is therefore not recommended (105,106). A CCB or other agent may be used based on the clinical characteristics of the patient.

Lipids

Compared to those without diabetes, patients with T2D have a significantly increased risk of ASCVD (107). Whereas blood glucose control is fundamental to prevention of microvascular complications, controlling atherogenic cholesterol particle concentrations is fundamental to prevention of macrovascular disease (i.e., ASCVD). To reduce the significant risk of ASCVD, including coronary heart disease (CHD), in T2D patients, early intensive management of dyslipidemia is warranted (see Comprehensive Type 2 Diabetes Management Algorithm—ASCVD Risk Factor Modifications Algorithm).

The classic major risk factors that modify the low-density-lipoprotein cholesterol (LDL-C) goal for all individuals include cigarette smoking, hypertension (BP ≥140/90 mm Hg or use of antihypertensive medications), high-density-lipoprotein cholesterol (HDL-C) <40 mg/dL, family history of CHD, and age ≥45 years for males or ≥55 years for females (108). Recognizing that T2D carries a high lifetime risk for developing ASCVD, risk should be stratified for primary prevention as high (diabetes with no other risk factors) or very high (diabetes plus one or more additional risk factors). In addition to hyperglycemia, most T2D patients have a syndrome of insulin resistance, which is characterized by several ASCVD risk factors, including hypertension, hypertriglyceridemia, low HDL-C, elevated apolipoprotein (apo) B and small dense LDL, and a procoagulant and pro-inflammatory milieu. Patients with T2D and a prior ASCVD event (i.e., recognized "clinical ASCVD") or chronic kidney disease (CKD) stage 3 or 4 are classified as *extreme* risk in this setting for secondary or recurrent events prevention. Risk stratification in this manner can guide management strategies.

Patients with diabetes, therefore, can be classified as high risk, very-high risk, or extreme risk; as such, the AACE recommends LDL-C targets of <100 mg/dL, <70 mg/dL, and <55 mg/dL; non-HDL-C targets of <130 mg/dL, <100 mg/dL, and <80 mg/dL; and apo B targets of <90 mg/dL, <80 mg/dL, and 70 mg/dL, respectively, with additional lipid targets shown in Table 1 (109-125) (see also Comprehensive Type 2 Diabetes Management Algorithm—ASCVD Risk Factor Modifications Algorithm). The atherogenic cholesterol goals appear identical for very-high-risk primary prevention and for very-high-risk secondary (or recurrent events) prevention. As randomized controlled trials (RCTs) and analyses continue to support the concept of "lowest is best," for the *very high* and especially the *extreme* ASCVD risk groups, AACE/ACE does not recognize a lower limit for the goals of targeted atherogenic lipoprotein markers (i.e., LDL-C, non–HDL-C, or Apo B) that correlate with lower major adverse cardiovascular events. A meta-analysis of 8 major statin trials demonstrated that those individuals achieving an LDL-C <50 mg/dL, a non–HDL-C <75 mg/dL, and apo B <50 mg/dL have the lowest ASCVD events (109). Furthermore, the primary outcome and subanalyses of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), a study involving 18,144 patients, provided evidence that lower LDL-C (53 mg/dL) and apo B (70 mg/dL) result in better outcomes in patients with diabetes after acute coronary syndromes (110). LDL particle number (LDL-P) number can also be useful as a target for treatment in patients with diabetes. However, in the absence of robust prospective clinical trial evidence, there is a lack of uniform agreement as to the goal levels. Suggested targets have been proposed as <1,200 for high risk and <1,000 for very high-risk patients. Data for LDL-P in patients now described as extreme risk are not established (126,127).

Some patients with T2D can achieve lipid profile improvements using lifestyle therapy (smoking cessation, physical activity, weight management, and healthy eating) (108). However, most patients will require pharmacotherapy to reach their target lipid levels and reduce their cardiovascular risk.

A statin should be used as first-line cholesterol-lowering drug therapy, unless contraindicated; current evidence supports a moderate- to high-intensity statin (128-131). Numerous RCTs and meta-analyses conducted in primary and secondary prevention populations have demonstrated that statins significantly reduce the risk of cardiovascular events and death in patients with T2D (111,128,130-133). However, considerable residual risk persists even after aggressive statin monotherapy in primary prevention patients with multiple cardiovascular risk factors and in secondary prevention patients with stable clinical ASCVD or acute coronary syndrome (ACS) (112,131,134). Although intensification of statin therapy (e.g., through use of higher dose or higher potency agents) can further reduce atherogenic cholesterol particles (primarily LDL-C) and the risk of ASCVD events (135), some residual risk will remain (136). Data from several studies have shown that even when LDL-C reaches an optimal level (20th percentile), non–HDL-C, apo B, and LDL-P levels can remain suboptimal (137). Furthermore, statin intolerance (usually muscle-related adverse effects) can limit the use of intensive statin therapy in some patients (138).

Other lipid-modifying agents should be utilized in combination with maximally tolerated statins when ther-

Table 1 AACE Lipid Targets for Patients With T2D or T2D Risk Factors (125)				
		Treatment goals		
Risk category	**Risk factors[a]/10-year risk[b]**	**LDL-C (mg/dL)**	**Non–HDL-C (mg/dL)**	**Apo B (mg/dL)**
Extreme risk	– Progressive ASCVD including unstable angina in patients after achieving an LDL-C <70 mg/dL – Established clinical cardiovascular disease in patients with DM, CKD 3/4, or HeFH – History of premature ASCVD (<55 male, <65 female)	<55	<80	<70
Very high risk	– Established or recent hospitalization for ACS, coronary, carotid, or peripheral vascular disease – Diabetes or CKD 3/4 with one or more risk factor(s) – HeFH	<70	<100	<80
High risk	≥2 risk factors and 10-year risk >10% or CHD risk equivalent[c], including diabetes or CKD 3/4 with no other risk factors	<100	<130	<90
Moderate risk	≥2 risk factors and 10-year risk <10%	<130	<160	NR
Low risk	≤1 risk factor	<160	<190	NR

Abbreviations: AACE = American Association of Clinical Endocrinologists; ACS = acute coronary syndrome; Apo = apolipoprotein; ASCVD = atherosclerotic cardiovascular disease; CHD = coronary heart disease; CKD = chronic kidney disease; DM = diabetes mellitus; HeFH = heterozygous familial hypercholesterolemia; HDL-C = high-density-lipoprotein cholesterol; LDL-C = low-density-lipoprotein cholesterol; NR = not recommended; T2D = type 2 diabetes.
[a]Major independent risk factors are high LDL-C, polycystic ovary syndrome, cigarette smoking, hypertension (blood pressure ≥140/90 mm Hg or on antihypertensive medication), low HDL-C (<40 mg/dL), family history of coronary artery disease (in males, first-degree relative younger than 55 years; in females, first-degree relative younger than 65 years), chronic renal disease (CKD) stage 3/4, evidence of coronary artery calcification and age (males ≥45 years; females ≥55 years). Subtract one risk factor if the person has high HDL-C.
[b]Framingham risk scoring is applied to determine 10-year risk.
[c]Coronary artery disease risk equivalents include diabetes and clinical manifestations of noncoronary forms of atherosclerotic disease (peripheral arterial disease, abdominal aortic aneurysm, and carotid artery disease).

apeutic levels of LDL-C, non–HDL-C, apo B, or LDL-P have not been reached:

- Ezetimibe inhibits intestinal absorption of cholesterol, reduces chylomicron production, decreases hepatic cholesterol stores, upregulates LDL receptors, and lowers apo B, non–HDL-C, LDL-C, and triglycerides (139). In IMPROVE-IT, the relative risk of ASCVD was reduced by 6.4% (*P* = .016) in patients taking simvastatin plus ezetimibe for 7 years (mean LDL-C: 54 mg/dL) compared to simvastatin alone (LDL-C: 70 mg/dL). The ezetimibe benefit was almost exclusively noted in the prespecified diabetes subgroup, which comprised 27% of the study population and in which the relative risk of ASCVD was reduced by 14.4% (*P* = .023) (110).

- Monoclonal antibody inhibitors of proprotein convertase subtilisin-kexin type 9 serine protease (PCSK9), a protein that regulates the recycling of LDL receptors, are approved by the FDA for primary prevention in patients with hetero- and homozygous familial hypercholesterolemia (HeFH and HoFH, respectively) or as secondary prevention in patients with clinical ASCVD who require additional LDL-C–lowering therapy.

This class of drugs meets a large unmet need for more aggressive lipid-lowering therapy beyond statins in an attempt to further reduce residual ASCVD risk in many persons with clinical ASCVD and diabetes. When added to maximal statin therapy, these once- or twice-monthly injectable agents reduce LDL-C by approximately 50%, raise HDL-C, and have favorable effects on other lipids (140-146). In the FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) study, evolocumab significantly reduced the risk of myocardial infarction, stroke, and coronary revascularization (147), and similar effects were seen with alirocumab in ODYSSEY Outcomes (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab Study) (148). In post hoc cardiovascular safety analyses of alirocumab and evolocumab added to statins with or without other lipid-lowering therapies, mean LDL-C levels of 48 mg/dL were associated with statistically significant relative risk reductions of 48 to 53% in major ASCVD events (141,142). Furthermore, a subgroup analysis of patients with diabetes taking

alirocumab demonstrated that a 59% LDL-C reduction was associated with an ASCVD event relative risk reduction trend of 42% (149).

- The highly selective bile acid sequestrant (BAS) colesevelam increases hepatic bile acid production by increasing elimination of bile acids, thereby decreasing hepatic cholesterol stores. This leads to an upregulation of LDL receptors; a reduction in LDL-C, non–HDL-C, apo B, and LDL-P; and improved glycemic status. There is a small compensatory increase in de novo cholesterol biosynthesis, which can be suppressed by the addition of statin therapies (150-152). Additionally, colesevelam may worsen hypertriglyceridemia (153).

- Fibrates have only small effects on lowering atherogenic cholesterol (5%) and are used mainly for lowering triglycerides. By lowering triglycerides, fibrates unmask residual atherogenic cholesterol in triglyceride-rich remnants (i.e., very-low-density-lipoprotein cholesterol). In progressively higher triglyceride settings, as triglycerides decrease, LDL-C increases, thus exposing the need for additional lipid therapies. As monotherapy, fibrates have demonstrated significantly favorable outcomes in populations with high non–HDL-C (154) and low HDL-C (155). The addition of fenofibrate to statins in the ACCORD study showed no benefit in the overall cohort in which mean baseline triglycerides and HDL-C were within normal limits (156). Subgroup analyses and meta-analyses of major fibrate trials, however, have shown a relative risk reduction for ASCVD events of 26 to 35% among patients with moderate dyslipidemia (triglycerides >200 mg/dL and HDL-C <40 mg/dL) (156-161).

- Niacin lowers apo B, LDL-C, and triglycerides in a dose-dependent fashion and is the most powerful lipid-modifying agent for raising HDL-C currently available (162), although it may reduce cardiovascular events through a mechanism other than an increase in HDL-C (163). Two trials designed to test the HDL-C–raising hypothesis (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes [AIM-HIGH] and Heart Protection Study 2—Treatment of HDL to Reduce the Incidence of Vascular Events [HPS2-THRIVE]) failed to show ASCVD protection during the 3- and 4-year trial periods, respectively (164,165); by design, between-group differences in LDL-C were nominal at 5 mg/dL and 10 mg/dL, respectively. Previous trials with niacin that showed cardiovascular benefits utilized higher doses of niacin, which were associated with much greater between-group differences in LDL-C, suggesting niacin benefits may result solely from its LDL-C–lowering properties (166). Although niacin may increase blood glucose, its beneficial effects appear to be greatest among patients with the highest baseline glucose levels and those with metabolic syndrome (167). As a result, it is particularly important to closely monitor glycemia in people with diabetes or prediabetes who are not receiving glucose-lowering treatment and taking niacin.

- Dietary intake of fish and omega-3 fish oil is associated with reductions in the risks of total mortality, sudden death, and coronary artery disease through various mechanisms of action other than lowering of LDL-C. In a large clinical trial, highly purified, prescription-grade, moderate-dose (1.8 g) eicosapentaenoic acid (EPA) added to a statin regimen was associated with a significant 19% reduction in risk of any major coronary event among Japanese patients with elevated total cholesterol (168) and a 22% reduction in CHD in patients with impaired fasting glucose or T2D (169). Among those with triglycerides >150 mg/dL and HDL-C <40 mg/dL, EPA treatment reduced the risk of coronary events by 53% (170). Other studies of lower doses (1 g) of omega-3 fatty acids (combined EPA and docosahexaenoic acid) in patients with baseline triglycerides <200 mg/dL have not demonstrated cardiovascular benefits (171,172). Recently, the REDUCE-IT (Reduction of Cardiovascular Events with EPA-Intervention Trial) study of icosapent ethyl, an EPA-only prescription-grade omega-3 fatty acid given at a dose of 4 g/day, demonstrated a 25% reduction in risk of major adverse cardiovascular events among patients with LDL-C levels below 100 mg/dL and triglyceride levels between 150 and 499 mg/dL (173). Studies evaluating other high-dose (4 g) prescription-grade omega-3 fatty acids in the setting of triglyceride levels >200 mg/dL are ongoing.

Relative to statin efficacy (30 to >50% LDL-C lowering), drugs such as ezetimibe, BAS, fibrates, and niacin have lesser LDL-C–lowering effects (7 to 20%) and ASCVD reduction (125). However, these agents can significantly lower LDL-C when utilized in various combinations, either in statin-intolerant patients or as add-on to maximally tolerated statins. Triglyceride-lowering agents such as prescription-grade omega-3 fatty acids, fibrates, and niacin are important agents that expose the atherogenic cholesterol within triglyceride-rich remnants, which require additional cholesterol lowering. PCSK9 inhibitors are currently indicated for adult patients with HeFH, HoFH, or clinical ASCVD as an adjunct to a lipid-management meal plan and maximally tolerated statin therapy, who require additional LDL-C lowering. Patients with diabetes and characteristics consistent with ASCVD risk equivalents are not currently candidates in the United States.

If triglyceride levels are severely elevated (>500 mg/dL), begin treatment with a very-low-fat meal plan and reduced intake of simple carbohydrates and initiate combinations of a fibrate, prescription-grade omega-

3-fatty acid, and/or niacin to reduce triglyceride levels and to prevent pancreatitis. Blood glucose control is also essential for triglyceride reduction. While no large clinical trials have been designed to test this objective, observational data and retrospective analyses support long-term dietary and lipid management of hypertriglyceridemia for prophylaxis against or treatment of acute pancreatitis (174,175).

T2D Pharmacotherapy

In patients with T2D, achieving the glucose and A1C targets requires a nuanced approach that balances age, comorbidities, hypoglycemia risk, and many other factors described above (6). The AACE supports an A1C goal of ≤6.5% (48 mmol/mol) for most patients or >6.5% if the lower target cannot be achieved without adverse outcomes. Significant reductions in the risk or progression of nephropathy were seen in the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) study, which targeted an A1C <6.5% in the intensive therapy group versus standard approaches. In ADVANCE, the starting A1C was 7.5% (58 mmol/mol), and rates of hypoglycemia were higher in the intensive therapy group (176). In the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial, intensive glycemic control significantly reduced the risk and/or progression of retinopathy, nephropathy, and neuropathy (177,178). However, in ACCORD, which involved older and middle-aged patients with long-standing T2D who were at high risk for or had established ASCVD and a baseline A1C >8.5% (69 mmol/mol), patients randomized to intensive glucose-lowering therapy (A1C target of <6.0% [42 mmol/mol]) had increased mortality (179). The excess mortality occurred only in patients whose A1C remained >7% (53 mmol/mol) despite intensive therapy, and this critical distinction is sometimes forgotten when the risk and benefits of intensive therapy are discussed. In the standard therapy group (A1C target 7 to 8% [53 to 64 mmol/mol]), mortality followed a U-shaped curve with increasing death rates at both low (<7%) and high (>8%) A1C levels (180). ACCORD showed that cardiovascular autonomic neuropathy may be another useful predictor of cardiovascular risk (181). A combination of cardiovascular autonomic neuropathy and symptoms of peripheral neuropathy increase the odds ratio to 4.55 for ASCVD and mortality (182). In the Veterans Affairs Diabetes Trial (VADT), which had a higher A1C target for intensively treated patients (1.5% lower than the standard treatment group), there were no between-group differences in ASCVD endpoints, cardiovascular death, or overall death during the 5.6-year study period (179,183). After approximately 10 years, however, VADT patients participating in an observational follow-up study were 17% less likely to have a major cardiovascular event if they received intensive therapy during the trial (*P*<.04; 8.6 fewer cardiovascular events per 1,000 person-years),

while mortality risk remained the same between treatment groups (184).

Severe hypoglycemia occurs more frequently with intensive glycemic control in RCTs where insulin and/or sulfonylureas (SUs) are utilized (176,179,183,185,186). In ACCORD, severe hypoglycemia may have accounted for a substantial portion of excess mortality among patients receiving intensive therapy, although the hazard ratio for hypoglycemia-associated deaths was higher in the standard treatment group (186).

Taken together, this evidence supports individualization of glycemic goals (see Comprehensive Type 2 Diabetes Management Algorithm—Glycemic Control Algorithm) (6). In adults with recent T2D onset and no clinically significant ASCVD, an A1C ≤6.5% (48 mmol/mol), if achieved without substantial hypoglycemia or other unacceptable consequences, may reduce the lifetime risk of micro- and macrovascular complications. A broader A1C range may be suitable for older patients and those at risk for hypoglycemia. A less stringent A1C >6.5% is appropriate for patients with a history of severe hypoglycemia, limited life expectancy, advanced renal disease or macrovascular complications, extensive comorbid conditions, or long-standing T2D in which the A1C goal has been difficult to attain despite intensive efforts, so long as the patient remains free of polydipsia, polyuria, polyphagia, or other hyperglycemia-associated symptoms. Therefore, selection of glucose-lowering agents should consider a patient's therapeutic goal, age, and other factors that impose limitations on treatment, as well as the attributes and adverse effects of each regimen. Regardless of the treatment selected, patients must be followed regularly and closely to ensure that glycemic goals are met and maintained.

The order of agents in each column of the Glycemic Control Algorithm suggests a hierarchy of recommended usage, and the length of each line reflects the strength of the expert consensus recommendation (see Comprehensive Type 2 Diabetes Management Algorithm—Glycemic Control Algorithm). Each medication's properties should be considered when selecting a therapy for individual patients (see Comprehensive Type 2 Diabetes Management Algorithm—Profiles of Antidiabetic Medications), and healthcare professionals should consult the FDA prescribing information for each agent.

- Metformin has a low risk of hypoglycemia, can promote modest weight loss, and has good antihyperglycemic efficacy at doses of 1,000 to 2,000 mg/day. Its effects are quite durable compared to SUs, and it also has robust cardiovascular safety relative to SUs (187-189). The FDA recently changed the package label for metformin use in CKD patients, lifting the previous contraindication in males with serum creatinine >1.5 mg/dL and females with serum creatinine >1.4 mg/dL (190,191). Newer CKD guidelines are

based on estimated glomerular filtration rate (eGFR), not on serum creatinine. Metformin can be used in patients with stable eGFR >30 mL/min/1.73 m^2; however, it should not be started in patients with an eGFR <45 mL/min/1.73 m^2. Reduction in total daily dose is prudent in patients with eGFR between 30 and 45 mL/min/1.73 m^2, and due to risk of lactic acidosis, it should not be used in patients with eGFR <30 mL/min/1.73 m^2 (192,193). In up to 16% of users, metformin is responsible for vitamin B12 malabsorption and/or deficiency (194,195), a causal factor in the development of anemia and peripheral neuropathy (196). In patients taking metformin who develop neuropathy, B12 should be monitored and supplements given to affected patients, if needed (197).

- Glucagon-like peptide 1 (GLP1) receptor agonists have robust A1C-lowering properties, are usually associated with weight loss and lipid and BP reductions (198,199), and are available in several formulations. In the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial, liraglutide significantly reduced the risk of nephropathy and of death from certain cardiovascular causes (200). Liraglutide has received FDA approval to reduce the risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in adults with T2D and established cardiovascular disease (201). Data from the SUSTAIN-6 trial with semaglutide and findings from the REWIND and HARMONY trials with dulaglutide and albiglutide, respectively, suggest other GLP1 receptor agonists also have cardiovascular disease benefits (202-204). GLP1 receptor agonists based on exendin-4 have been proven to be safe in cardiovascular disease, but they have not been shown to confer cardiovascular benefits (205,206). The risk of hypoglycemia with GLP1 receptor agonists is low (207), and they reduce fluctuations in both fasting and postprandial glucose levels by stimulating glucose-dependent insulin secretion and suppressing glucagon secretion. GLP1 receptor agonists should not be used in patients with a personal or family history of medullary thyroid carcinoma or those with multiple endocrine neoplasia syndrome type 2. Exenatide should not be used if creatinine clearance is <30 mL/min. No dose adjustment is required for liraglutide, semaglutide, and dulaglutide in CKD, although renal function should be monitored in patients reporting severe adverse gastrointestinal reactions (208). No studies have confirmed that incretin agents cause pancreatitis (209); however, GLP1 receptor agonists should be used cautiously, if at all, in patients with a history of pancreatitis and discontinued if pancreatitis develops. Some GLP1 receptor agonists may retard gastric emptying, especially with initial use. Therefore, use in patients with gastroparesis or severe gastro-esophageal reflux disease requires careful monitoring and dose adjustment.

- Sodium-glucose cotransporter 2 (SGLT2) inhibitors have a glucosuric effect that results in decreased A1C, weight, and systolic BP. Empagliflozin was associated with significantly lower rates of all-cause and cardiovascular death and lower risk of hospitalization for heart failure in the EMPA-REG OUTCOME trial (Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes) (210). Treatment with canagliflozin significantly reduced the risk of the combined cardiovascular outcomes of cardiovascular death, myocardial infarction, and nonfatal stroke, as well as hospitalization for heart failure, but increased the risk of amputation in CANVAS (Canagliflozin Cardiovascular Assessment Study) (211). In DECLARE-TIMI (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction), dapagliflozin reduced a composite of cardiovascular death and heart failure hospitalizations but did not significantly lower the combined risk of cardiovascular death and nonfatal myocardial infarction and stroke (212). Heart failure–related endpoints appear to account for most of the observed benefits in the published studies; a cardiovascular outcomes study of ertugliflozin is ongoing. In adults with T2D and established ASCVD, empagliflozin has an FDA-approved indication to reduce cardiac mortality and canagliflozin is indicated to reduce the risk of major cardiovascular events (213,214). In their respective cardiovascular outcomes trials, canagliflozin, dapagliflozin, and empagliflozin reduced progression of kidney disease (210-212). In the CREDENCE (Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy) trial, which specifically assessed kidney benefits in patients with stage 3 CKD and albuminuria, canagliflozin significantly reduced the risk of a composite of end-stage kidney disease (dialysis, transplantation, or a sustained eGFR of <15 mL/min/1.73 m^2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes by 30%. The risk of hospitalization for heart failure was also reduced by 39% (215). In DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), a study that involved patients who had heart failure with reduced ejection fraction (58% of whom did not have diabetes), dapagliflozin was associated with a 26% reduction in risk of heart failure worsening or cardiovascular death (216). SGLT2 inhibitors are associated with increased risk of mycotic genital infections and slightly increased LDL-C levels, and because

of their mechanism of action, they have limited efficacy in patients with an eGFR <45 mL/min/1.73 m^2. Dehydration due to increased diuresis may lead to initial renal impairment, hypotension, syncope, and falls (214,217-219). There are ongoing investigations into postmarketing reports of SGLT2 inhibitor–associated diabetic ketoacidosis (DKA), which has been reported to occur in type 1 diabetes (T1D) and T2D patients with less than expected hyperglycemia (euglycemic DKA) (218,220). In a recent review of 2,500 cases of SGLT2 inhibitor–associated DKA, 5% of patients with T1D treated with SGLT2 inhibitors developed DKA and 10% developed ketosis (220). In T2D, the incidence rate ranged from 0.16 to 0.76 events per 1,000 patient-years (221,222). After a thorough review of the evidence during an October 2015 meeting, an AACE/ACE Scientific and Clinical Review expert consensus group recommended stopping SGLT2 inhibitors 24 to 48 hours prior to scheduled surgeries and anticipated metabolically stressful activities (e.g., extreme sports) and that patients taking SGLT2 inhibitors with insulin should avoid very-low-carbohydrate meal plans and excess alcohol intake (223). The class is also associated with an increased risk of necrotizing fasciitis of the perineum (Fournier's gangrene), a rare but serious genital infection (213,214,224,225).

- Dipeptidyl peptidase 4 (DPP4) inhibitors exert antihyperglycemic effects by inhibiting DPP4 and thereby enhancing levels of GLP1 and other incretin hormones. This action stimulates glucose-dependent insulin synthesis and secretion and suppresses glucagon secretion. DPP4 inhibitors have modest A1C-lowering properties; are weight-neutral; and are available in combination tablets with metformin, SGLT2 inhibitors, and a TZD. The risk of hypoglycemia with DPP4 inhibitors is low (226,227). The DPP4 inhibitors, except linagliptin, are excreted by the kidneys; therefore, dose adjustments are advisable for patients with renal dysfunction. These agents should be used with caution in patients with a history of pancreatitis (and stopped if pancreatitis occurs), although a causative association has not been established (209). DPP4 inhibitors have been shown to have neutral effects on cardiovascular outcomes (228-230). A possible slightly increased risk of heart failure with saxagliptin and alogliptin was found in the respective cardiovascular outcome trials (231,232), and a warning is included in the product labels for these agents.

- The TZDs, the only antihyperglycemic agents to directly reduce insulin resistance, have relatively potent A1C-lowering properties, a low risk of hypoglycemia, and durable glycemic effects (81,188,233).

Pioglitazone may confer ASCVD benefits (81,82,234), while rosiglitazone has a neutral effect on ASCVD risk (235,236). Side effects that have limited TZD use include weight gain, increased bone fracture risk in postmenopausal females and elderly males, and elevated risk for chronic edema or heart failure (237-241). These side effects may be mitigated by using a moderate dose (e.g., ≤30 mg) of pioglitazone, or in the case of fluid retention, by combining the TZD with an SGLT2 inhibitor. A possible association with bladder cancer has largely been refuted (242).

- In general, alpha glucosidase inhibitors (AGIs) have modest A1C-lowering effects and low risk for hypoglycemia (243). Clinical trials have suggested ASCVD benefit in patients with impaired glucose tolerance and diabetes (75,244). Side effects (e.g., bloating, flatulence, diarrhea) have limited their use in the United States; slow titration of premeal doses may mitigate the side effects and facilitate tolerance. These agents should be used with caution in patients with CKD.

- The insulin-secretagogue SUs have relatively potent A1C-lowering effects but lack durability and are associated with weight gain and hypoglycemia (188,245). SUs have the highest risk of serious hypoglycemia of any noninsulin therapy, and analyses of large datasets have raised concerns regarding the cardiovascular safety of this class when the comparator is metformin, which may itself have cardioprotective properties (189,246). The secretagogue glinides have somewhat lower A1C-lowering effects and a shorter half-life and thus carry a lower risk of prolonged hypoglycemia relative to SUs.

- Colesevelam, a BAS, modestly lowers glucose, does not cause hypoglycemia, and decreases LDL-C. A perceived modest efficacy for both A1C and LDL-C lowering as well as gastrointestinal intolerance (constipation and dyspepsia, which occurs in 10% of users) may contribute to limited use. In addition, colesevelam can increase triglyceride levels in people with pre-existing triglyceride elevations, but this is somewhat preventable by concomitant statin use (247).

- The quick-release sympatholytic dopamine receptor agonist bromocriptine mesylate has modest glucose-lowering properties (248) and does not cause hypoglycemia. It can cause nausea and orthostasis, which may be mitigated by limiting use to less than maximal recommended doses and should not be used in patients taking antipsychotic drugs. Bromocriptine mesylate may be associated with reduced cardiovascular event rates (249,250).

For patients with recent-onset T2D or mild hyperglycemia (A1C <7.5% [58 mmol/mol]), lifestyle therapy plus antihyperglycemic monotherapy (preferably with metformin) is recommended (see Comprehensive Type 2 Diabetes Management Algorithm—Glycemic Control Algorithm).

GLP1 receptor agonists and SGLT2 inhibitors with proven ASCVD and/or CKD benefits may be preferred in patients with those complications. Other acceptable alternatives to metformin as initial therapy include DPP4 inhibitors and TZDs. AGIs, SUs, and glinides may also be appropriate as monotherapy for select patients.

In patients who do not reach their glycemic target on metformin monotherapy, metformin should be continued in combination with other agents, including insulin. Patients who present with an A1C >7.5% (whether newly diagnosed or not) and who are not already taking any antihyperglycemic agents should be started initially on metformin plus another agent in addition to lifestyle therapy (245) (see Comprehensive Type 2 Diabetes Management Algorithm—Glycemic Control Algorithm). In metformin-intolerant patients, two drugs with complementary mechanisms of action from other classes should be considered. Fixed-dose (single-pill) combinations of oral agents including metformin and/or SGLT2 inhibitors, DPP4 inhibitors, TZDs, and SUs are available for the treatment of T2D. Fixed-ratio combinations of GLP1 receptor agonists and basal insulin are also available.

The addition of a third agent may be needed to enhance treatment efficacy (see Comprehensive Type 2 Diabetes Management Algorithm—Glycemic Control Algorithm), although any third-line agent is likely to have somewhat less efficacy than when the same medication is used as first- or second-line therapy. Patients with A1C >9.0% (75 mmol/mol) who are symptomatic (presenting with polyuria, polydipsia, or polyphagia) would likely derive greatest benefit from the addition of insulin, but if presenting without significant symptoms these patients may initiate therapy with maximum doses of two or three other medications. Therapy intensification should include intensified lifestyle therapy and anti-obesity treatment (when indicated), not just antihyperglycemic medication. Therapy de-intensification is also possible when control targets are met.

Certain patient populations are at higher risk for adverse treatment-related outcomes, underscoring the need for individualized therapy. Although several antihyperglycemic drug classes carry a low risk of hypoglycemia (e.g., metformin, GLP1 receptor agonists, SGLT2 inhibitors, DPP4 inhibitors, and TZDs), significant hypoglycemia can still occur when these agents are used in combination with an insulin secretagogue or exogenous insulin. When such combinations are used, one should consider lowering the dose of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. Many antihyperglycemic agents (e.g., metformin, GLP1 receptor agonists, SGLT2 inhibitors, some DPP4 inhibitors, AGIs, and SUs) have limitations in patients with impaired renal function and may require dose adjustments or special precautions (see Comprehensive Type 2 Diabetes Management Algorithm—Profiles of Antidiabetic Medications). In general, diabetes therapy does not require modification for mild to moderate liver disease, but the risk of hypoglycemia increases in severe cases.

Insulin

Insulin is the most potent antihyperglycemic agent. However, many factors should be considered when deciding to start insulin therapy and choosing the initial insulin formulation (see Comprehensive Type 2 Diabetes Management Algorithm—Algorithm for Adding/Intensifying Insulin). These decisions, made in collaboration with the patient, depend greatly on each patient's motivation, cardiovascular and end-organ complications, age, risk of hypoglycemia, and overall health status, as well as cost considerations. Patients taking two oral antihyperglycemic agents who have an A1C >8.0% (64 mmol/mol) and/or long-standing T2D are less likely to reach their target A1C with a third oral antihyperglycemic agent. Although adding a GLP1 receptor agonist as the third agent may successfully lower glycemia, eventually many patients will still require insulin (251,252). When insulin becomes necessary, a single daily dose of basal insulin should be added to the regimen. The dosage should be adjusted at regular and initially fairly short intervals, measured in days, to achieve the targeted glycemic goal while avoiding hypoglycemia. Studies (253-255) have shown that titration is equally effective whether it is guided by the healthcare professional or a patient who has been instructed in SMBG or CGM.

Basal insulin analogs are preferred over neutral protamine Hagedorn (NPH) insulin because a single basal analog dose provides a relatively flat serum insulin concentration for 24 hours or longer. Although basal insulin analogs and NPH have been shown to be equally effective in reducing A1C in clinical trials, insulin analogs caused significantly less hypoglycemia (253,254,256-258), especially newer ultra-long-acting analogs that demonstrate minimal variability (259).

The newest basal insulin formulations—glargine U300 and degludec U100 and U200—have more prolonged and stable pharmacokinetic and pharmacodynamic characteristics than glargine U100 and detemir (259-261). RCTs have reported equivalent glycemic control and lower rates of severe or confirmed hypoglycemia, particularly nocturnal hypoglycemia, with these newer basal insulins compared to glargine U100 and detemir (259,262-267). Cardiovascular outcomes were equivalent in the DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events) trial comparing insulin degludec to insulin glargine U100 (259).

Premixed insulins provide less dosing flexibility and have been associated with a higher frequency of hypoglycemic events compared to basal and basal-bolus regimens (268-270). Nevertheless, there are some patients for whom a simpler regimen using these agents is a reason-

able compromise, in which case premixed analog insulin may be preferred over premixed human due to lower rates of hypoglycemia.

Patients whose basal insulin regimens (which may already include metformin) fail to provide glucose control may benefit from the addition of a GLP1 receptor agonist, SGLT2 inhibitor, or DPP4 inhibitor (if not already taking one of these agents; see Comprehensive Type 2 Diabetes Management Algorithm—Algorithm for Adding/Intensifying Insulin). When added to insulin therapy, the incretins and SGLT2 inhibitors enhance glucose reductions and may minimize weight gain without increasing the risk of hypoglycemia. The incretins also increase endogenous insulin secretion in response to meals, reducing postprandial hyperglycemia (251,271-276). The combination of basal insulin with a GLP1 receptor agonist may offer greater efficacy than the oral agents; fixed-ratio combinations of GLP1 receptor agonists and basal insulins are available. Depending on patient response, basal insulin dose may need to be reduced to avoid hypoglycemia.

Patients whose glycemia remains uncontrolled while receiving basal insulin in combination with oral agents or GLP1 receptor agonists may require mealtime insulin to cover postprandial hyperglycemia. Rapid-acting injectable insulin analogs (lispro, glulisine, aspart, or fast-acting aspart) or inhaled insulin are preferred over regular human insulin because the former have a more rapid onset and offset of action and are associated with less hypoglycemia (277,278). However, for those who find the more costly analog insulins unaffordable, human regular insulin or premixed human insulin for T2D are less expensive options (279). Prandial insulin should be considered when the total daily dose of basal insulin is greater than 0.5 U/kg. Beyond this dose, the risk of hypoglycemia increases markedly without significant benefit in reducing A1C (280). The simplest approach is to cover the largest meal with a prandial injection of a rapid-acting insulin analog or inhaled insulin and then add additional meal coverage later, as needed. Several RCTs have shown that the stepwise addition of prandial insulin to basal insulin is safe and effective in achieving target A1C with a low rate of hypoglycemia (281-283). A full basal-bolus program is the most effective insulin regimen and provides greater flexibility for patients with variable mealtimes and meal carbohydrate content, although this type of program has been associated with weight gain (283). Continuous insulin delivery devices may be appropriate for some patients with T2D who would otherwise require multiple daily injections of basal and rapid-acting insulin.

Pramlintide is indicated for use with basal-bolus insulin regimens. Pioglitazone is indicated for use with insulin at doses of 15 and 30 mg, but this approach may aggravate weight gain. There are no specific approvals for the use of SUs with insulin, but when they are used together, the risks of both weight gain and hypoglycemia increase (284,285).

It is important to avoid hypoglycemia. Approximately 7 to 15% of insulin-treated patients in the UKPDS (United Kingdom Prospective Diabetes Study) experienced at least one annual episode of hypoglycemia (286), and based on other studies, 1 to 2% of patients with T2D experience severe hypoglycemia (287,288). In a study using CGM, 49% of patients experienced at least one blood glucose <70 mg/dL over a 5-day study period, and 10% experienced a blood glucose <50 mg/dL (289). Several large RCTs found that T2D patients with a history of one or more severe hypoglycemic events have an approximately 2- to 4-fold higher death rate (186,290). Severe hypoglycemia may precipitate fatal ventricular arrhythmia through an effect on baroreflex sensitivity (291), or hypoglycemia may be a marker for persons at higher risk of death, rather than the proximate cause of death (288). SMBG or CGM is necessary in all patients taking insulin, with increased frequency of monitoring recommended for patients taking meal-time insulin. One possible safety measure for prevention of hypoglycemia is the use of CGM that provides real-time glucose data with or without alarms for hyper- and hypoglycemic excursions and events (292).

Patients receiving insulin also gain about 1 to 3 kg more weight than those receiving other agents.

Role of CGM

While A1C has been established as a biomarker for overall glycemic exposure and correlates with long-term diabetic complications, it is not very useful for making specific recommendations for choice of antihyperglycemic medications in individual patients with T2D. The extent to which A1C reflects glycemia varies by ethnicity and by multiple comorbidities. A1C is also not very helpful to patients for understanding their diabetes, the impact of lifestyle on glycemic control, or their response to interventions. Patients may also be reluctant to advance therapies if they do not really understand their glycemic pattern or are unable to perform SMBG at an adequate frequency. CGM helps patients achieve that understanding, which may help with adherence. For this reason, CGM is preferred over SMBG.

Significant advances have been made in accuracy and availability of CGM devices. As the use of these devices has expanded, both by clinicians and patients, their role in decision-making and management of diabetes has been evolving. While few controlled studies on CGM use in T2D have been published, a current consensus is that use of professional CGM (i.e., the device owned by the clinician's practice) should be considered in patients who have not reached their glycemic target after 3 months of the initial antihyperglycemic therapy and for those who require therapy that is associated with risks of hypoglycemia (i.e., SU, glinide, or insulin) (293,294). The frequency of use would depend on the stability of therapies.

Use of personal CGM devices (i.e., those owned by the patient), on the other hand, should be considered for those patients who are on intensive insulin therapy (3 to 4 injections/day or on insulin pump), for those with history of hypoglycemia unawareness, or those with recurrent hypoglycemia (293,294). While these devices could be used intermittently in those who appear stable on their therapy, most patients meeting these criteria will need to use this technology on a continual basis.

As experience with CGM in T2D grows, we anticipate more frequent use of both professional and personal devices, which may increasingly replace SMBG.

ACKNOWLEDGMENT

DISCLOSURES

Chair of the Task Force
Dr. Alan J. Garber: reports no potential conflicts of interest.

Task Force Members
Dr. Martin Julian Abrahamson: Novo Nordisk, consultant.

Dr. Joshua I. Barzilay; Dr. Jeffrey R. Garber; Dr. Susan L. Samson: report no potential conflicts of interest.

Dr. Lawrence Blonde: AstraZeneca, Gilead Sciences, Inc., Merck, Janssen Pharmaceuticals, Novo Nordisk, Sanofi, consultant; Sanofi, Janssen Pharmaceuticals, Novo Nordisk, speaker; Novo Nordisk, Sanofi, research grant support.

Dr. Michael A. Bush: Eli Lilly, Novo Nordisk, AstraZeneca, Janssen, speaker and/or consultant.

Dr. Ralph Anthony DeFronzo: Novo Nordisk AstraZeneca, speaker; Boehringer Ingelheim, Janssen Pharmaceuticals, Merck and AstraZeneca, research grant support; Advisory Board: Novo Nordisk, Astra Zeneca, Janssen, Intarcia.

Dr. Daniel Einhorn: Novo Nordisk, Eli Lilly, Abbott, Sanofi, Janssen, AstraZeneca, Boehringer-Ingelheim, consultant, speaker and/or research grant support; Halozyme, stock ownership.

Dr. W. Timothy Garvey: Novo Nordisk, Boehringer-Ingelheim, BOYDSense, Sanofi, Gilead, Amgen, consultant; Pfizer, Sanofi, and Novo Nordisk, research grant support.

Dr. George Grunberger: Eli Lilly, Novo Nordisk, Sanofi, Boehringer Ingelheim, speaker; Medtronic, Novo Nordisk, research grant support.

Dr. Yehuda Handelsman: Amarin, AstraZeneca, BI-Lilly, Merck, Sanofi, consultant and/or speaker; Amgen, AstraZeneca, BMS, Gan & Lee, Mylan, Novo Nordisk, and Sanofi, research grant support.

Dr. Irl B. Hirsch: Abbott, Roche, Bigfoot, Becton Dickinson, consulting fees; Medtronic Diabetes, research grant support.

Dr. Paul S. Jellinger: Regeneron/Sanofi, Amgen, Janssen Pharmaceuticals, Merck, Amarin, AstraZeneca, speaker.

Dr. Janet B. McGill: Aegerion, consultant and/or speaker.

Dr. Jeffrey I. Mechanick: Abbott Nutrition International, consultant.

Dr. Leigh Perreault: Novo Nordisk, Sanofi, AstraZeneca, Merck, Boehringer-Ingelheim, and Janssen, consultant and/or speaker.

Dr. Paul D. Rosenblit: Akcea, Esperion, Novo Nordisk, consultant; Akcea, Amarin, Amgen, Merck, speaker; Amgen, Dexcom, GlaxoSmithKine, Ionis, Lilly, Mylan, Novo Nordisk, research grant support.

Dr. Guillermo E. Umpierrez: Sanofi, Dexcom, Novo Nordisk, research grant support.

REFERENCES

1. **Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC.** Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. *Diabetes*. 2003;52:102-110.
2. **Kahn SE.** The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. *Diabetologia*. 2003;46:3-19.
3. **Kahn SE, Lachin JM, Zinman B, et al.** Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. *Diabetes*. 2011;60:1552-1560.
4. **Mechanick JI, Hurley DL, Garvey WT.** Adiposity-based chronic disease as a new diagnostic term: the American Association of Clinical Endocrinologists and American College of Endocrinology position statement. *Endocr Pract*. 2017;23:372-378.
5. **Mechanick JI, Garber AJ, Grunberger G, Handelsman Y, Garvey WT.** Dysglycemia-based chronic disease: an American Association of Clinical Endocrinologists position statement. *Endocr Pract*. 2018;24:995-1011.
6. **Handelsman Y, Bloomgarden ZT, Grunberger G, et al.** American Association of Clinical Endocrinologists and American College of Endocrinology: clinical practice guidelines for developing a diabetes mellitus comprehensive care plan--2015. *Endocr Pract*. 2015;21(suppl 1):1-87.
7. **Wadden TA, West DS, Neiberg RH, et al.** One-year weight losses in the Look AHEAD study: factors associated with success. *Obesity (Silver Spring)*. 2009;17:713-722.
8. **Look AHEAD Research Group, Pi-Sunyer X, Blackburn G, et al.** Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. *Diabetes Care*. 2007;30:1374-1383.
9. **Diabetes Prevention Program Research Group, Ratner R, Goldberg R, et al.** Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. *Diabetes Care*. 2005;28:888-894.
10. **Hoskin MA, Bray GA, Hattaway K, et al.** Prevention of diabetes through the lifestyle intervention: lessons learned from the

Diabetes Prevention Program and Outcomes Study and its translation to practice. *Curr Nutr Rep*. 2014;3:364-378.

11. **Mechanick JI, Adams S, Davidson JA, et al.** Transcultural diabetes care in the United States—a position statement by the American Association of Clinical Endocrinologists. *Endocr Pract*. 2019;25:729-765.

12. **Evert AB, Boucher JL, Cypress M, et al.** Nutrition therapy recommendations for the management of adults with diabetes. *Diabetes Care*. 2013;36:3821-3842.

13. **Bergenstal RM, Johnson M, Powers MA, et al.** Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. *Diabetes Care*. 2008;31:1305-1310.

14. **Keogh JB, Clifton PM.** Meal replacements for weight loss in type 2 diabetes in a community setting. *J Nutr Metab*. 2012;2012:918571.

15. **Ditschuneit HH, Flechtner-Mors M, Johnson TD, Adler G.** Metabolic and weight-loss effects of a long-term dietary intervention in obese patients. *Am J Clin Nutr*. 1999;69:198-204.

16. **Flechtner-Mors M, Ditschuneit HH, Johnson TD, Suchard MA, Adler G.** Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results. *Obes Res*. 2000;8:399-402.

17. **Sbrocco T, Nedegaard RC, Stone JM, Lewis EL.** Behavioral choice treatment promotes continuing weight loss: preliminary results of a cognitive-behavioral decision-based treatment for obesity. *J Consult Clin Psychol*. 1999;67:260-266.

18. **Fuller PR, Perri MG, Leermakers EA, Guyer LK.** Effects of a personalized system of skill acquisition and an educational program in the treatment of obesity. *Addict Behav*. 1998;23:97-100.

19. **Meyers AW, Graves TJ, Whelan JP, Barclay DR.** An evaluation of a television-delivered behavioral weight loss program: are the ratings acceptable? *J Consult Clin Psychol*. 1996;64:172-178.

20. **Perri MG, McAllister DA, Gange JJ, Jordan RC, McAdoo G, Nezu AM.** Effects of four maintenance programs on the long-term management of obesity. *J Consult Clin Psychol*. 1988;56:529-534.

21. **Metz JA, Stern JS, Kris-Etherton P, et al.** A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction. *Arch Intern Med*. 2000;160:2150-2158.

22. **Gonzalez-Campoy JM, St Jeor ST, Castorino K, et al.** Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: cosponsored by the American Association of Clinical Endocrinologists/the American College of Endocrinology and the Obesity Society. *Endocr Pract*. 2013;19(suppl 3):1-82.

23. **Balducci S, Alessi E, Cardelli P, Cavallo S, Fallucca F, Pugliese G.** Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis: response to Snowling and Hopkins. *Diabetes Care*. 2007;30:e25; author reply e26.

24. **Manders RJ, Van Dijk JW, van Loon LJ.** Low-intensity exercise reduces the prevalence of hyperglycemia in type 2 diabetes. *Med Sci Sports Exerc*. 2010;42:219-225.

25. **Hansen D, Dendale P, Jonkers RA, et al.** Continuous low- to moderate-intensity exercise training is as effective as moderate-to high-intensity exercise training at lowering blood HbA(1c) in obese type 2 diabetes patients. *Diabetologia*. 2009;52:1789-1797.

26. **Praet SF, Manders RJ, Lieverse AG, et al.** Influence of acute exercise on hyperglycemia in insulin-treated type 2 diabetes. *Med Sci Sports Exerc*. 2006;38:2037-2044.

27. **De Feyter HM, Praet SF, van den Broek NM, et al.** Exercise training improves glycemic control in long-standing insulin-treated type 2 diabetic patients. *Diabetes Care*. 2007;30:2511-2513.

28. **Church TS, Blair SN, Cocreham S, et al.** Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial [Erratum in JAMA. 2011;305:892]. *JAMA*. 2010;304:2253-2262.

29. **Balducci S, Zanuso S, Nicolucci A, et al.** Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES). *Arch Intern Med*. 2010;170:1794-1803.

30. **Vinik AI, Vinik EJ, Colberg SR, Morrison S.** Falls risk in older adults with type 2 diabetes. *Clin Geriatr Med*. 2015;31:89-99, viii.

31. **Colberg SR, Sigal RJ, Fernhall B, et al.** Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement executive summary. *Diabetes Care*. 2010;33:2692-2696.

32. **McNeil J, Doucet É, Chaput JP.** Inadequate sleep as a contributor to obesity and type 2 diabetes. *Can J Diabetes*. 2013;37:103-108.

33. **Cappuccio FP, Cooper D, D'Elia L, Strazzullo P, Miller MA.** Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. *Eur Heart J*. 2011;32:1484-1492.

34. **Patel SR, Malhotra A, White DP, Gottlieb DJ, Hu FB.** Association between reduced sleep and weight gain in women. *Am J Epidemiol*. 2006;164:947-954.

35. **Gottlieb DJ, Redline S, Nieto FJ, et al.** Association of usual sleep duration with hypertension: the Sleep Heart Health Study. *Sleep*. 2006;29:1009-1014.

36. **Chaput JP, Després JP, Bouchard C, Tremblay A.** Short sleep duration is associated with reduced leptin levels and increased adiposity: results from the Quebec family study. *Obesity (Silver Spring)*. 2007;15:253-261.

37. **Ayas NT, White DP, Manson JE, et al.** A prospective study of sleep duration and coronary heart disease in women. *Arch Intern Med*. 2003;163:205-209.

38. **Lindberg E, Carter N, Gislason T, Janson C.** Role of snoring and daytime sleepiness in occupational accidents. *Am J Respir Crit Care Med*. 2001;164:2031-2035.

39. **Winkelman JW, Redline S, Baldwin CM, Resnick HE, Newman AB, Gottlieb DJ.** Polysomnographic and health-related quality of life correlates of restless legs syndrome in the Sleep Heart Health Study. *Sleep*. 2009;32:772-778.

40. **Valencia-Flores M, Orea A, Castaño VA, et al.** Prevalence of sleep apnea and electrocardiographic disturbances in morbidly obese patients. *Obes Res*. 2000;8:262-269.

41. **Anderson RJ, Freedland KE, Clouse RE, Lustman PJ.** The prevalence of comorbid depression in adults with diabetes: a meta-analysis. *Diabetes Care*. 2001;24:1069-1078.

42. **Anderson RJ, Grigsby AB, Freedland KE, et al.** Anxiety and poor glycemic control: a meta-analytic review of the literature. *Int J Psychiatry Med*. 2002;32:235-247.

43. **Harkness E, Macdonald W, Valderas J, Coventry P, Gask L, Bower P.** Identifying psychosocial interventions that improve both physical and mental health in patients with diabetes: a systematic review and meta-analysis. *Diabetes Care*. 2010;33:926-930.

44. **Frühbeck G, Busetto L, Dicker D, et al.** The ABCD of obesity: an EASO position statement on a diagnostic term with clinical and scientific implications. *Obes Facts*. 2019;12:131-136.

45. **Garvey WT, Garber AJ, Mechanick JI, et al.** American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. *Endocr Pract*. 2014;20:977-989.

46. **Mechanick JI, Garber AJ, Handelsman Y, Garvey WT.** American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine. *Endocr Pract*. 2012;18:642-648.

47. **Garvey WT, Mechanick JI, Brett EM, et al.** American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. *Endocr Pract*. 2016;22(suppl 3):1-203.

48. **Garvey WT.** New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approach. *Endocr Pract*. 2013;19:864-874.

49. **Bray GA, Ryan DH.** Medical therapy for the patient with obesity. *Circulation*. 2012;125:1695-1703.

50. **Kip KE, Marroquin OC, Kelley DE, et al.** Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. *Circulation*. 2004;109:706-713.

51. **Yusuf S, Hawken S, Ounpuu S, et al.** Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. *Lancet*. 2005;366:1640-1649.

52. **Lean MEJ, Leslie WS, Barnes AC, et al.** Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. *Lancet Diabetes Endocrinol*. 2019;7:344-355.

53. **Hutton B, Fergusson D.** Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypo-caloric diet: a systematic review of randomized clinical trials. *Am J Clin Nutr*. 2004;80:1461-1468.

54. **Torgerson JS, Hauptman J, Boldrin MN, Sjöström L.** XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients [Erratum in Diabetes Care. 2004;27:856]. *Diabetes Care*. 2004;27:155-161.

55. **Smith SR, Weissman NJ, Anderson CM, et al.** Multicenter, placebo-controlled trial of lorcaserin for weight management. *N Engl J Med*. 2010;363:245-256.

56. **O'Neil PM, Smith SR, Weissman NJ, et al.** Randomized place-bo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. *Obesity (Silver Spring)*. 2012;20:1426-1436.

57. **Fidler MC, Sanchez M, Raether B, et al.** A one-year random-ized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. *J Clin Endocrinol Metab*. 2011;96:3067-3077.

58. **Garvey WT, Ryan DH, Look M, et al.** Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a random-ized, placebo-controlled, phase 3 extension study. *Am J Clin Nutr*. 2012;95:297-308.

59. **Garvey WT, Ryan DH, Henry R, et al.** Prevention of type 2 diabe-tes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. *Diabetes Care*. 2014;37:912-921.

60. **Allison DB, Gadde KM, Garvey WT, et al.** Controlled-release phentermine/topiramate in severely obese adults: a random-ized controlled trial (EQUIP). *Obesity (Silver Spring)*. 2012;20:330-342.

61. **Gadde KM, Allison DB, Ryan DH, et al.** Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. *Lancet*. 2011;377:1341-1352.

62. **Garvey WT, Ryan DH, Bohannon NJ, et al.** Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended-release. *Diabetes Care*. 2014;37:3309-3316.

63. **Apovian CM, Aronne L, Rubino D, et al.** A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). *Obesity (Silver Spring)*. 2013;21:935-943.

64. **Hollander P, Gupta AK, Plodkowski R, et al.** Effects of naltrex-one sustained-release/bupropion sustained-release combina-tion therapy on body weight and glycemic parameters in over-weight and obese patients with type 2 diabetes. *Diabetes Care*. 2013;36:4022-4029.

65. **Wadden TA, Foreyt JP, Foster GD, et al.** Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. *Obesity (Silver Spring)*. 2011;19:110-120.

66. **Greenway FL, Fujioka K, Plodkowski RA, et al.** Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2010;376:595-605.

67. **Wadden TA, Hollander P, Klein S, et al.** Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. *Int J Obes (Lond)*. 2013;37:1443-1451.

68. **Astrup A, Carraro R, Finer N, et al.** Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. *Int J Obes (Lond)*. 2012;36:843-854.

69. **Astrup A, Rössner S, Van Gaal L, et al.** Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. *Lancet*. 2009;374:1606-1616.

70. **Pi-Sunyer X, Astrup A, Fujioka K, et al.** A randomized, controlled trial of 3.0 mg of liraglutide in weight management. *N Engl J Med*. 2015;373:11-22.

71. **Mechanick JI, Youdim A, Jones DB, et al.** Clinical practice guide-lines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery. *Endocr Pract*. 2013;19:337-372.

72. **Garber AJ, Handelsman Y, Einhorn D, et al.** Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. *Endocr Pract*. 2008;14:933-946.

73. **Diabetes Prevention Program Research Group, Knowler WC, Barrett-Connor E, et al.** Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002;346:393-403.

74. **le Roux CW, Astrup A, Fujioka K, et al.** 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. *Lancet*. 2017;389:1399-1409.

75. **STOP-NIDDM Trial Research Group, Chiasson JL, Josse RG, et al.** Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. *JAMA*. 2003;290:486-494.

76. **STOP-NIDDM Trial Research Group, Chiasson JL, Josse RG, et al.** Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. *Lancet*. 2002;359:2072-2077.

77. **Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, et al.** 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study [Erratum in Lancet. 2009;374:2054]. *Lancet*. 2009;374:1677-1686.

78. **DREAM (Diabetes REduction Assessment with rampipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, et al.** Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial [Erratum in: Lancet. 2006;368:1770]. *Lancet*. 2006;368:1096-1105.

79. **Diabetes Prevention Program Research Group, Knowler WC, Hamman RF, et al.** Prevention of type 2 diabetes with trogli-tazone in the Diabetes Prevention Program. *Diabetes*. 2005;54:1150-1156.

80. **DeFronzo RA, Tripathy D, Schwenke DC, et al.** Pioglitazone for diabetes prevention in impaired glucose tolerance. *N Engl J Med*. 2011;364:1104-1115.

81. **Dormandy JA, Charbonnel B, Eckland DJA, et al.** Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet*. 2005;366:1279-1289.

82. **Kernan WN, Viscoli CM, Furie KL, et al.** Pioglitazone after ischemic stroke or transient ischemic attack. *N Engl J Med*. 2016;374:1321-1331.

83. **Bangalore S, Kumar S, Lobach I, Messerli FH.** Blood pres-sure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials. *Circulation*. 2011;123:2799-2810.

84. **McBrien K, Rabi DM, Campbell N, et al.** Intensive and stan-dard blood pressure targets in patients with type 2 diabetes mellitus: systematic review and meta-analysis. *Arch Intern Med*. 2012;172:1296-1303.

85. **Sleight P, Redon J, Verdecchia P, et al.** Prognostic value of blood pressure in patients with high vascular risk in the ongo-ing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial study. *J Hypertens*. 2009;27:1360-1369.

86. **ACCORD Study Group, Cushman WC, Evans GW, et al.** Effects of intensive blood-pressure control in type 2 diabetes melli-tus. *N Engl J Med*. 2010;362:1575-1585.

87. **Whelton PK, He J, Cutler JA, et al.** Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. *JAMA*. 1997;277:1624-1632.

88. **Azadbakht L, Mirmiran P, Esmaillzadeh A, Azizi T, Azizi F.** Beneficial effects of a Dietary Approaches to Stop Hypertension

eating plan on features of the metabolic syndrome. *Diabetes Care*. 2005;28:2823-2831.

89. **Buse JB, Ginsberg HN, Bakris GL, et al.** Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. *Diabetes Care*. 2007;30:162-172.

90. **Levitan EB, Wolk A, Mittleman MA.** Consistency with the DASH diet and incidence of heart failure. *Arch Intern Med*. 2009;169:851-857.

91. **Liese AD, Nichols M, Sun X, D'Agostino RB Jr, Haffner SM.** Adherence to the DASH Diet is inversely associated with incidence of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. *Diabetes Care*. 2009;32:1434-1436.

92. **Sacks FM, Svetkey LP, Vollmer WM, et al.** Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. *N Engl J Med*. 2001;344:3-10.

93. **Vollmer WM, Sacks FM, Ard J, et al.** Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. *Ann Intern Med*. 2001;135:1019-1028.

94. **Corrao G, Bagnardi V, Zambon A, La Vecchia C.** A meta-analysis of alcohol consumption and the risk of 15 diseases. *Prev Med*. 2004;38:613-619.

95. **Costanzo S, Di Castelnuovo A, Donati MB, Iacoviello L, de Gaetano G.** Cardiovascular and overall mortality risk in relation to alcohol consumption in patients with cardiovascular disease. *Circulation*. 2010;121:1951-1959.

96. **Stewart K.** Exercise and Hypertension. ACSM's Resource Manual for Guidelines for Exercise Testing and Prescription. 4th ed. Baltimore, MD: Lippincott, Williams & Wilkens; 2001: 285-291.

97. **James PA, Oparil S, Carter BL, et al.** 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014;311:507-520.

98. **Heart Outcomes Prevention Evaluation Study Investigators.** Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. [Erratum in *Lancet*. 2000;356:860]. *Lancet*. 2000;355:253-259.

99. **Hansson L, Zanchetti A, Carruthers SG, et al.** Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. *Lancet*. 1998;351:1755-1762.

100. **Dahlof B, Devereux RB, Kjeldsen SE, et al.** Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet*. 2002;359:995-1003.

101. **Rahman M, Pressel S, Davis BR, et al.** Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Arch Intern Med*. 2005;165:936-946.

102. **Telmisartan Randomised AssessmeNt Study in ACEiswcDI, Yusuf S, Teo K, et al.** Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. *Lancet*. 2008;372:1174-1183.

103. **Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD.** Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. *Diabetes Care*. 2000;23:888-892.

104. **Jamerson K, Weber MA, Bakris GL, et al.** Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med*. 2008;359:2417-2428.

105. **Parving HH, Brenner BM, McMurray JJ, et al.** Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *N Engl J Med*. 2012;367:2204-2213.

106. **Fried LF, Emanuele N, Zhang JH, et al.** Combined angiotensin inhibition for the treatment of diabetic nephropathy. *N Engl J Med*. 2013;369:1892-1903.

107. **Benjamin EJ, Virani SS, Callaway CW, et al.** Heart disease and stroke statistics—2018 update: a report from the American Heart Association. *Circulation*. 2018;137:e67-e492.

108. **National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A.** Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002;106:3143-3421.

109. **Boekholdt SM, Hovingh GK, Mora S, et al.** Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. *J Am Coll Cardiol*. 2014;64:485-494.

110. **Cannon CP, Blazing MA, Giugliano RP, et al.** Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*. 2015;372:2387-2397.

111. **Heart Protection Study Collaborative Group.** MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002;360:7-22.

112. **Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E.** Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. *J Am Coll Cardiol*. 2005;45: 1644-1648.

113. **Barter PJ, Ballantyne CM, Carmena R, et al.** Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. *J Intern Med*. 2006;259:247-258.

114. **Brunzell JD, Davidson M, Furberg CD, et al.** Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. *Diabetes Care*. 2008;31: 811-822.

115. **Grundy SM, Cleeman JI, Merz CN, et al.** Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation*. 2004;110: 227-239.

116. **Lloyd-Jones DM, Wilson PW, Larson MG, et al.** Framingham risk score and prediction of lifetime risk for coronary heart disease. *Am J Cardiol*. 2004;94:20-24.

117. **McClelland RL, Jorgensen NW, Budoff M, et al.** 10-Year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study). *J Am Coll Cardiol*. 2015;66:1643-1653.

118. **Ridker PM, Buring JE, Rifai N, Cook NR.** Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. *JAMA*. 2007;297:611-619.

119. **Sever PS, Dahlöf B, Poulter NR, et al.** Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet*. 2003;361:1149-1158.

120. **Shepherd J, Blauw GJ, Murphy MB, et al.** Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet*. 2002;360:1623-1630.

121. **Smith SC Jr, Allen J, Blair SN, et al.** AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. *Circulation*. 2006;113: 2363-2372.

122. **Stevens RJ, Kothari V, Adler AI, Stratton IM.** The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). *Clin Sci (Lond)*. 2001;101:671-679.

123. **Stone NJ.** Lipid management: current diet and drug treatment options. *Am J Med*. 1996;101:4A40S-48S; discussion 48S-49S.

124. **Weiner DE, Tighiouart H, Amin MG, et al.** Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. *J Am Soc Nephrol*. 2004;15:1307-1315.

125. **Jellinger PS, Handelsman Y, Rosenblit PD, et al.** American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and

prevention of atherosclerosis. *Endocr Pract*. 2017;23(suppl 2): 1-87.

126. **Toth PP, Grabner M, Punekar RS, Quimbo RA, Cziraky MJ, Jacobson TA.** Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. *Atherosclerosis*. 2014;235:585-591.

127. **Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr.** Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. *J Clin Lipidol*. 2011;5:105-113.

128. **Colhoun HM, Betteridge DJ, Durrington PN, et al.** Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet*. 2004;364:685-696.

129. **Knopp RH, d'Emden M, Smilde JG, Pocock SJ.** Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). *Diabetes Care*. 2006;29:1478-1485.

130. **Cholesterol Treatment Trialists (CTT) Collaboration, Baigent C, Blackwell L, et al.** Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*. 2010;376:1670-1681.

131. **Cholesterol Treatment Trialists (CTT) Collaborators, Kearney PM, Blackwell L, et al.** Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet*. 2008;371:117-125.

132. **Athyros VG, Papageorgiou AA, Symeonidis AN, et al.** Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. *Angiology*. 2003;54: 679-690.

133. **Ahmed S, Cannon CP, Murphy SA, Braunwald E.** Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. *Eur Heart J*. 2006;27:2323-2329.

134. **de Lemos JA, Blazing MA, Wiviott SD, et al.** Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. *JAMA*. 2004;292:1307-1316.

135. **Shepherd J, Barter P, Carmena R, et al.** Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. *Diabetes Care*. 2006;29:1220-1226.

136. **Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E.** Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. *J Am Coll Cardiol*. 2006;48:438-445.

137. **Sniderman AD.** Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice. *J Clin Lipidol*. 2008;2:36-42.

138. **Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B.** Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. *Cardiovasc Drugs Ther*. 2005;19:403-414.

139. **Masuda D, Nakagawa-Toyama Y, Nakatani K, et al.** Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. *Eur J Clin Invest*. 2009;39:689-698.

140. **Blom DJ, Hala T, Bolognese M, et al.** A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. *N Engl J Med*. 2014;370:1809-1819.

141. **Robinson JG, Farnier M, Krempf M, et al.** Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. *N Engl J Med*. 2015;372:1489-1499.

142. **Sabatine MS, Giugliano RP, Wiviott SD, et al.** Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. *N Engl J Med*. 2015;372:1500-1509.

143. **Ramasamy I.** Recent advances in physiological lipoprotein metabolism. *Clin Chem Lab Med*. 2014;52:1695-1727.

144. **Zhang XL, Zhu QQ, Zhu L, et al.** Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. *BMC Med*. 2015;13:123.

145. **Verbeek R, Stoekenbroek RM, Hovingh GK.** PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia. *Eur J Pharmacol*. 2015;763(Pt A):38-47.

146. **Bays H, Gaudet D, Weiss R, et al.** Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. *J Clin Endocrinol Metab*. 2015;100:3140-3148.

147. **Sabatine MS, Giugliano RP, Keech AC, et al.** Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017;376:1713-1722.

148. **Steg PG.** Evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab—ODYSSEY OUTCOMES. American College of Cardiology Annual Scientific Session (ACC 2018). Orlando, FL; 2018.

149. **Colhoun HM, Ginsberg HN, Leiter LA, et al.** Efficacy and safety of alirocumab in individuals with diabetes: analyses from the ODYSSEY LONG TERM study. 51st Annual Meeting of the European Association for the Study of Diabetes. Stockholm, Sweden; 2015.

150. **Davidson MH, Dillon MA, Gordon B, et al.** Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. *Arch Intern Med*. 1999;159:1893-1900.

151. **Handelsman Y.** Role of bile acid sequestrants in the treatment of type 2 diabetes. *Diabetes Care*. 2011;34(suppl 2):S244-S250.

152. **Rosenson RS, Abby SL, Jones MR.** Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. *Atherosclerosis*. 2009;204:342-344.

153. **Aggarwal S, Loomba RS, Arora RR.** Efficacy of colesevelam on lowering glycemia and lipids. *J Cardiovasc Pharmacol*. 2012;59:198-205.

154. **Frick MH, Elo O, Haapa K, et al.** Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. *N Engl J Med*. 1987;317:1237-1245.

155. **Rubins HB, Robins SJ, Collins D, et al.** Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. *N Engl J Med*. 1999;341:410-418.

156. **ACCORD Study Group, Ginsberg HN, Elam MB, et al.** Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med*. 2010;362:1563-1574.

157. **Manninen V, Tenkanen L, Koskinen P, et al.** Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. *Circulation*. 1992;85:37-45.

158. **Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P.** Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. *J Cardiovasc Pharmacol*. 2011;57:267-272.

159. **Scott R, O'Brien R, Fulcher G, et al.** Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. *Diabetes Care*. 2009;32:493-498.

160. **Sacks FM, Carey VJ, Fruchart JC.** Combination lipid therapy in type 2 diabetes. *N Engl J Med*. 2010;363:692-694; author reply 694-695.

161. **Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B.** Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. *Atherosclerosis*. 2011;217:492-498.

162. **Carlson LA.** Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. *J Intern Med*. 2005;258:94-114.

163. **Pan J, Lin M, Kesala RL, Van J, Charles MA.** Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes. *Diabetes Obes Metab*. 2002;4:255-261.

164. **Boden WE, Probstfield JL, Anderson T, et al.** Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med*. 2011;365:2255-2267.

165. **HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al.** Effects of extended-release niacin with laropiprant in high-risk patients. *N Engl J Med*. 2014;371:203-212.

166. **Lavigne PM, Karas RH.** The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. *J Am Coll Cardiol*. 2013;61:440-446.

167. **Canner PL, Furberg CD, Terrin ML, McGovern ME.** Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). *Am J Cardiol*. 2005;95:254-257.

168. **Yokoyama M, Origasa H, Matsuzaki M, et al.** Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. *Lancet*. 2007;369:1090-1098.

169. **Oikawa S, Yokoyama M, Origasa H, et al.** Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). *Atherosclerosis*. 2009;206:535-539.

170. **Saito Y, Yokoyama M, Origasa H, et al.** Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). *Atherosclerosis*. 2008;200:135-140.

171. **Roncaglioni MC, Tombesi M, Avanzini F, et al.** n-3 fatty acids in patients with multiple cardiovascular risk factors. *N Engl J Med*. 2013;368:1800-1808.

172. **Bosch J, Gerstein HC, Dagenais GR, et al.** n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. *N Engl J Med*. 2012;367:309-318.

173. **Bhatt DL, Steg PG, Miller M, et al.** Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med*. 2019;380:11-22.

174. **Hegele RA, Ginsberg HN, Chapman MJ, et al.** The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. *Lancet Diabetes Endocrinol*. 2014;2:655-666.

175. **Christian JB, Arondekar B, Buysman EK, Jacobson TA, Snipes RG, Horwitz RI.** Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemia. *Am J Med*. 2014;127:36-44.e1.

176. **ADVANCE Collaborative Group, Patel A, MacMahon S, et al.** Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2008;358:2560-2572.

177. **Ismail-Beigi F, Craven T, Banerji MA, et al.** Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. *Lancet*. 2010;376:419-430.

178. **ACCORD Study Group, Chew EY, Ambrosius WT, et al.** Effects of medical therapies on retinopathy progression in type 2 diabetes. *N Engl J Med*. 2010;363:233-244.

179. **Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al.** Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med*. 2008;358:2545-2559.

180. **Riddle MC, Ambrosius WT, Brillon DJ, et al.** Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. *Diabetes Care*. 2010;33:983-990.

181. **Pop-Busui R, Evans GW, Gerstein HC, et al.** Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Diabetes Care*. 2010;33:1578-1584.

182. **Vinik A.** The approach to the management of the patient with neuropathic pain. *J Clin Endocrinol Metab*. 2010;95:4802-4811.

183. **Veterans Affairs Diabetes Trial Investigators, Duckworth W, Abraira C, et al.** Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med*. 2009;360:129-139.

184. **Hayward RA, Reaven PD, Wiitala WL, et al.** Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2015;372:2197-2206.

185. **ACCORD Study Group, Gerstein HC, Miller ME, et al.** Long-term effects of intensive glucose lowering on cardiovascular outcomes. *N Engl J Med*. 2011;364:818-828.

186. **Bonds DE, Miller ME, Bergenstal RM, et al.** The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. *BMJ*. 2010;340:b4909.

187. **Bailey CJ, Turner RC.** Metformin. *N Engl J Med*. 1996;334:574-579.

188. **Kahn SE, Haffner SM, Heise MA, et al.** Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N Engl J Med*. 2006;355:2427-2443.

189. **Roumie CL, Hung AM, Greevy RA, et al.** Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. *Ann Intern Med*. 2012;157:601-610.

190. Glucophage (metformin hydrochloride) tablets. Princeton, NJ: Bristol-Myers Squibb Co; 2017.

191. **U.S. Food and Drug Administration.** FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Silver Spring, MD: U.S. Food and Drug Administration; 2016. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm493244.htm. Accessed December 8, 2019.

192. **Kidney Disease: Improving Global Outcomes CKD Work Group.** KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl*. 2013;3:1-150.

193. **Lipska KJ, Bailey CJ, Inzucchi SE.** Use of metformin in the setting of mild-to-moderate renal insufficiency. *Diabetes Care*. 2011;34:1431-1437.

194. **Reinstatler L, Qi YP, Williamson RS, Garn JV, Oakley GP Jr.** Association of biochemical B12 deficiency with metformin therapy and vitamin B12 supplements: the National Health and Nutrition Examination Survey, 1999-2006. *Diabetes Care*. 2012;35:327-333.

195. **Leishear K, Boudreau RM, Studenski SA, et al.** Relationship between vitamin B12 and sensory and motor peripheral nerve function in older adults. *J Am Geriatr Soc*. 2012;60:1057-1063.

196. **Wile DJ, Toth C.** Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. *Diabetes Care*. 2010;33:156-161.

197. **Singh AK, Kumar A, Karmakar D, Jha RK.** Association of B12 deficiency and clinical neuropathy with metformin use in type 2 diabetes patients. *J Postgrad Med*. 2013;59:253-257.

198. **Deacon CF, Mannucci E, Ahrén B.** Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis. *Diabetes Obes Metab*. 2012;14:762-767.

199. **Sun F, Wu S, Wang J, et al.** Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. *Clin Ther*. 2015;37:225-241.e8.

200. **Marso SP, Daniels GH, Brown-Frandsen K, et al.** Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375:311-322.

201. Victoza (liraglutide rDNA origin) injection prescribing information. Princeton, NJ: Novo Nordisk, Inc; 2017.

202. **Marso SP, Bain SC, Consoli A, et al.** Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med*. 2016;375:1834-1844.

203. **Gerstein HC, Colhoun HM, Dagenais GR, et al.** Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet*. 2019;394:121-130.

204. **Hernandez AF, Green JB, Janmohamed S, et al.** Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. *Lancet*. 2018;392:1519-1529.

205. **Pfeffer MA, Claggett B, Diaz R, et al.** Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. *N Engl J Med*. 2015;373:2247-2257.

206. **Holman RR, Bethel MA, Mentz RJ, et al.** Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2017;377:1228-1239.

207. **Leech CA, Dzhura I, Chepurny OG, Schwede F, Genieser HG, Holz GG.** Facilitation of ss-cell K(ATP) channel sulfonylurea

sensitivity by a cAMP analog selective for the cAMP-regulated guanine nucleotide exchange factor Epac. *Islets*. 2010;2:72-81.

208. **Davies M, Chatterjee S, Khunti K.** The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. *Clin Pharmacol*. 2016;8:61-81.

209. **Parks M, Rosebraugh C.** Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy. *N Engl J Med*. 2010;362:774-777.

210. **Zinman B, Wanner C, Lachin JM, et al.** Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*. 2015;373:2117-2128.

211. **Neal B, Perkovic V, Mahaffey KW, et al.** Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med*. 2017;377:644-657.

212. **Wiviott SD, Raz I, Bonaca MP, et al.** Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2019;380:347-357.

213. Jardiance (empagliflozin) prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2018.

214. Invokana (canagliflozin) prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2018.

215. **Perkovic V, Jardine MJ, Neal B, et al.** Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med*. 2019;380:2295-2306.

216. **McMurray JJV, Solomon SD, Inzucchi SE, et al.** Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med*. 2019;381:1995-2008.

217. **Bloomgarden Z.** Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment. *J Diabetes*. 2013;5:225-227.

218. **Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB.** Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. *Diabetes Care*. 2015;38:1687-1693.

219. **Nauck MA.** Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. *Drug Des Devel Ther*. 2014;8:1335-1380.

220. **Fadini GP, Bonora BM, Avogaro A.** SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. *Diabetologia*. 2017;60:1385-1389.

221. **Umpierrez GE.** Diabetes: SGLT2 inhibitors and diabetic ketoacidosis—a growing concern. *Nat Rev Endocrinol*. 2017;13:441-442.

222. **Erondu N, Desai M, Ways K, Meininger G.** Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. *Diabetes Care*. 2015;38:1680-1686.

223. **Handelsman Y, Henry RR, Bloomgarden ZT, et al.** American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. *Endocr Pract*. 2016;22:753-762.

224. Farxiga (dapagliflozin) prescribing information. Princeton, NJ: Bristol-Myers Squibb Company; 2019.

225. Steglatro (ertugliflozin) prescribing information. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; 2018.

226. **Deacon CF.** Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. *Diabetes Obes Metab*. 2011;13:7-18.

227. **Ahrén B.** Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin—diabetes control and potential adverse events. *Best Pract Res Clin Endocrinol Metab*. 2009;23:487-498.

228. **White WB, Cannon CP, Heller SR, et al.** Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *N Engl J Med*. 2013;369:1327-1335.

229. **Scirica BM, Bhatt DL, Braunwald E, et al.** Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med*. 2013;369:1317-1326.

230. **Green JB, Bethel MA, Armstrong PW, et al.** Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2015;373:232-242.

231. **Zannad F, Cannon CP, Cushman WC, et al.** Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. *Lancet*. 2015;385:2067-2076.

232. **Scirica BM, Braunwald E, Raz I, et al.** Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. *Circulation*. 2014;130:1579-1588.

233. **DeFronzo RA.** From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes*. 2009;58:773-795.

234. **Lincoff AM, Wolski K, Nicholls SJ, Nissen SE.** Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. *JAMA*. 2007;298:1180-1188.

235. **Home PD, Pocock SJ, Beck-Nielsen H, et al.** Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. *Lancet*. 2009;373:2125-2135.

236. **Hiatt WR, Kaul S, Smith RJ.** The cardiovascular safety of diabetes drugs—insights from the rosiglitazone experience. *N Engl J Med*. 2013;369:1285-1287.

237. **Bolen S, Feldman L, Vassy J, et al.** Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus [Erratum in *Ann Intern Med*. 2007;147:887]. *Ann Intern Med*. 2007;147:386-399.

238. **Kahn SE, Zinman B, Lachin JM, et al.** Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). *Diabetes Care*. 2008;31:845-851.

239. **Schwartz AV, Sellmeyer DE, Vittinghoff E, et al.** Thiazolidinedione use and bone loss in older diabetic adults. *J Clin Endocrinol Metab*. 2006;91:3349-3354.

240. **Ferwana M, Firwana B, Hasan R, et al.** Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. *Diabet Med*. 2013;30:1026-1032.

241. **Viscoli CM, Inzucchi SE, Young LH, et al.** Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial. *J Clin Endocrinol Metab*. 2017;102:914-922.

242. **Lewis JD, Habel LA, Quesenberry CP, et al.** Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. *JAMA*. 2015;314:265-277.

243. **Rosak C, Mertes G.** Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations. *Diabetes Metab Syndr Obes*. 2012;5:357-367.

244. **Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M.** Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. *Eur Heart J*. 2004;25:10-16.

245. **Phung OJ, Scholle JM, Talwar M, Coleman CI.** Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. *JAMA*. 2010;303:1410-1418.

246. **Forst T, Hanefeld M, Jacob S, et al.** Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. *Diab Vasc Dis Res*. 2013;10:302-314.

247. **Fonseca VA, Handelsman Y, Staels B.** Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. *Diabetes Obes Metab*. 2010;12:384-392.

248. **Defronzo RA.** Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. *Diabetes Care*. 2011;34:789-794.

249. **Gaziano JM, Cincotta AH, O'Connor CM, et al.** Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. *Diabetes Care*. 2010;33:1503-1508.

250. **Gaziano JM, Cincotta AH, Vinik A, Blonde L, Bohannon N, Scranton R.** Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. *J Am Heart Assoc*. 2012;1:e002279.

251. **Devries JH, Bain SC, Rodbard HW, et al.** Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. *Diabetes Care*. 2012;35:1446-1454.

252. **Rosenstock J, Rodbard HW, Bain SC, et al.** One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. *J Diabetes Complications*. 2013;27:492-500.

253. **Riddle MC, Rosenstock J, Gerich J, Insulin Glargine Study Investigators.** The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. *Diabetes Care*. 2003;26:3080-3086.

254. **Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P.** A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. *Diabetes Care*. 2006;29:1269-1274.

255. **Blackberry ID, Furler JS, Ginnivan LE, et al.** An exploratory trial of basal and prandial insulin initiation and titration for type 2 diabetes in primary care with adjunct retrospective continuous glucose monitoring: INITIATION study. *Diabetes Res Clin Pract*. 2014;106:247-255.

256. **Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A.** Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. *Diabetes Care*. 2005;28:950-955.

257. **Monami M, Marchionni N, Mannucci E.** Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. *Diabetes Res Clin Pract*. 2008;81:184-189.

258. **Home PD, Fritsche A, Schinzel S, Massi-Benedetti M.** Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. *Diabetes Obes Metab*. 2010;12:772-779.

259. **Marso SP, McGuire DK, Zinman B, et al.** Efficacy and safety of degludec versus glargine in type 2 diabetes. *N Engl J Med*. 2017;377:723-732.

260. **Heise T, Hövelmann U, Nosek L, Hermanski L, Bøttcher SG, Haahr H.** Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. *Expert Opin Drug Metab Toxicol*. 2015;11:1193-1201.

261. **Davies M, Sasaki T, Gross JL, et al.** Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trial. *Diabetes Obes Metab*. 2016;18:96-99.

262. **Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T.** New insulin glargine 300 Units . mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units . mL-1. *Diabetes Care*. 2015;38:637-643.

263. **Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD.** New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). *Diabetes Care*. 2014;37: 2755-2762.

264. **Garber AJ, King AB, Del Prato S, et al.** Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. *Lancet*. 2012;379:1498-1507.

265. **Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM.** Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. *Diabetes Care*. 2013;36:2536-2542.

266. **Meneghini L, Atkin SL, Gough SC, et al.** The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. *Diabetes Care*. 2013;36:858-864.

267. **Zinman B, Philis-Tsimikas A, Cariou B, et al.** Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). *Diabetes Care*. 2012;35:2464-2471.

268. **Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H.** Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. *Diabetes Care*. 2005;28:254-259.

269. **Tunis SL, Sauriol L, Minshall ME.** Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada. *Appl Health Econ Health Policy*. 2010;8:267-280.

270. **Yki-Järvinen H, Kauppila M, Kujansuu E, et al.** Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. *N Engl J Med*. 1992;327:1426-1433.

271. **Wilding JP, Woo V, Soler NG, et al.** Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. *Ann Intern Med*. 2012;156:405-415.

272. **Rosenstock J, Jelaska A, Frappin G, et al.** Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. *Diabetes Care*. 2014;37:1815-1823.

273. **Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R.** Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. *Curr Med Res Opin*. 2012;28:513-523.

274. **Buse JB, Bergenstal RM, Glass LC, et al.** Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. *Ann Intern Med*. 2011;154:103-112.

275. **Russell-Jones D, Vaag A, Schmitz O, et al.** Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. *Diabetologia*. 2009;52:2046-2055.

276. **Vilsbøll T, Rosenstock J, Yki-Järvinen H, et al.** Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. *Diabetes Obes Metab*. 2010;12:167-177.

277. **Hirsch IB.** Insulin analogues. *N Engl J Med*. 2005;352:174-183.

278. **McGill JB, Ahn D, Edelman SV, Kilpatrick CR, Santos Cavaiola T.** Making insulin accessible: does inhaled insulin fill an unmet need? *Adv Ther*. 2016;33:1267-1278.

279. **Lipska KJ, Hirsch IB, Riddle MC.** Human insulin for type 2 diabetes: an effective, less-expensive option. *JAMA*. 2017;318: 23-24.

280. **Arnolds S, Heise T, Flacke F, Sieber J.** Common standards of basal insulin titration in type 2 diabetes. *J Diabetes Sci Technol*. 2013;7:771-788.

281. **Owens DR, Luzio SD, Sert-Langeron C, Riddle MC.** Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. *Diabetes Obes Metab*. 2011;13:1020-1027.

282. **Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA, Orals Plus Apidra and Lantus (OPAL) Study Group.** Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. *Diabetes Obes Metab*. 2008;10:1178-1185.

283. **Leahy JL.** Insulin therapy in type 2 diabetes mellitus. *Endocrinol Metab Clin North Am*. 2012;41:119-144.

284. **Peyrot M, Rubin RR, Polonsky WH, Best JH.** Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs. *Curr Med Res Opin*. 2010;26:1047-1054.

285. **Wright A, Burden AC, Paisey RB, Cull CA, Holman RR.** Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). *Diabetes Care*. 2002;25:330-336.

286. **United Kingdom Hypoglycaemia Study Group.** Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. *Diabetologia*. 2007;50:1140-1147.

287. **DeWitt DE, Hirsch IB.** Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. *JAMA*. 2003;289: 2254-2264.

288. **Moghissi E, Ismail-Beigi F, Devine RC.** Hypoglycemia: minimizing its impact in type 2 diabetes. *Endocr Pract*. 2013;19: 526-535.

289. **Gehlaut RR, Dogbey GY, Schwartz FL, Marling CR, Shubrook JH.** Hypoglycemia in type 2 diabetes--more common than you

think: a continuous glucose monitoring study. *J Diabetes Sci Technol*. 2015;9:999-1005.

290. **Zoungas S, Patel A, Chalmers J, et al.** Severe hypoglycemia and risks of vascular events and death. *N Engl J Med*. 2010;363: 1410-1418.

291. **Cryer PE.** Death during intensive glycemic therapy of diabetes: mechanisms and implications. *Am J Med*. 2011;124:993-996.

292. **McGill JB, Ahmann A.** Continuous glucose monitoring with multiple daily insulin treatment: outcome studies. *Diabetes Technol Ther.* 2017;19:S3-S12.

293. **Bailey TS, Grunberger G, Bode BW, et al.** American Association of Clinical Endocrinologists and American College of Endocrinology 2016 outpatient glucose monitoring consensus statement. *Endocr Pract*. 2016;22:231-261.

294. **Grunberger G, Bailey T, Camacho PM, et al.** Proceedings from the American Association of Clinical Endocrinologists and American College of Endocrinology consensus conference on glucose monitoring. *Endocr Pract*. 2015;21:522-533.

2020

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS
AMERICAN COLLEGE OF ENDOCRINOLOGY

AACE/ACE COMPREHENSIVE
TYPE 2 DIABETES
MANAGEMENT ALGORITHM

TABLE OF CONTENTS

COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM

PRINCIPLES OF THE AACE/ACE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM

1. Lifestyle modification underlies all therapy (e.g., weight control, physical activity, sleep, etc.)

2. Avoid hypoglycemia

3. Avoid weight gain

4. Individualize all glycemic targets (A1C, FPG, PPG)

5. Optimal A1C is ≤6.5%, or as close to normal as is safe and achievable

6. Therapy choices are patient centric based on A1C at presentation and shared decision-making

7. Choice of therapy reflects ASCVD, CHF, and renal status

8. Comorbidities must be managed for comprehensive care

9. Get to goal as soon as possible—adjust at ≤3 months until at goal

10. Choice of therapy includes ease of use and affordability

11. CGM is highly recommended, as available, to assist patients in reaching goals safely

LIFESTYLE THERAPY

RISK STRATIFICATION FOR DIABETES COMPLICATIONS

INTENSITY STRATIFIED BY BURDEN OF OBESITY AND RELATED COMPLICATIONS

Nutrition
- Maintain optimal weight
- Calorie restriction (manage increased weight)
- Plant-based diet; high polyunsaturated and monounsaturated fatty acids

+

- Avoid *trans* fatty acids; limit saturated fatty acids
- Technological aids

+

- Structured counseling
- Meal replacement

Physical Activity
- 150 min/week moderate exertion (e.g., walking, stair climbing)
- Strength training
- Increase as tolerated

+

- Structured program
- Wearable technologies

+

- Medical evaluation/clearance
- Medical supervision

Sleep
- About 6-8 hours per night
- Basic sleep hygiene

+

- Screen sleep disturbances
- Home sleep study

+

- Referral to sleep study

Behavioral Support
- Community engagement
- Alcohol moderation

+

- Discuss mood with HCP

+

- Formal behavioral therapy

Smoking Cessation
- No tobacco products

+

- Nicotine replacement therapy and medications as tolerated

+

- Referral to structured program

COMPLICATIONS-CENTRIC MODEL FOR CARE OF THE PATIENT WITH OVERWEIGHT/OBESITY (ADIPOSITY-BASED CHRONIC DISEASE)

STEP 1

EVALUATION FOR COMPLICATIONS AND STAGING

CARDIOMETABOLIC DISEASE | BIOMECHANICAL COMPLICATIONS

	COMPLICATIONS	
NO COMPLICATIONS		
BMI ≥25	BMI ≥25	
OVERWEIGHT OR OBESITY	MILD TO MODERATE	SEVERE
STAGE 0	STAGE 1	STAGE 2

BMI <25

NO OVERWEIGHT OR OBESITY

STEP 2

SELECT:

Therapeutic targets for improvement in complications + Treatment modality + Treatment intensity based on staging

Lifestyle Therapy: Physician/RD counseling, web/remote program, structured multidisciplinary program

Medical Therapy (BMI ≥27): Individualize care by selecting one of the following based on efficacy, safety, and patients' clinical profile: phentermine, orlistat, lorcaserin, phentermine/topiramate ER, naltrexone/bupropion, liraglutide 3 mg

Surgical Therapy (BMI ≥35): Endoscopic procedures, gastric banding, sleeve, or bypass

STEP 3

If therapeutic targets for complications not met, intensify lifestyle, medical, and/or surgical treatment modalities for greater weight loss. Obesity is a chronic progressive disease and requires commitment to long-term therapy and follow-up.

PREDIABETES ALGORITHM

IFG (100–125) | IGT (140–199) | METABOLIC SYNDROME (NCEP 2001)

LIFESTYLE THERAPY
(Including Medically Assisted Weight Loss)

TREAT HYPERGLYCEMIA
FPG >100 | 2-hour PG >140

MULTIPLE PRE-DM CRITERIA

Consider with Caution
- TZD
- GLP-1RA

1 PRE-DM CRITERION

Low-risk Medications
- Metformin
- Acarbose

Intensify Weight Loss Therapies

If hyperglycemia persists

TREAT ASCVD RISK FACTORS

WEIGHT LOSS THERAPIES

NORMAL GLYCEMIA

Progression

OVERT DIABETES

PROCEED TO GLYCEMIC CONTROL ALGORITHM

ASCVD RISK FACTOR MODIFICATIONS ALGORITHM

DYSLIPIDEMIA ROUTE

HYPERTENSION ROUTE

LEGEND

Orlistat, lorcaserin, phentermine/topiramate ER, naltrexone/bupropion, liraglutide 3 mg, or bariatric surgery as indicated for obesity treatment

ASCVD RISK FACTOR MODIFICATIONS ALGORITHM

DYSLIPIDEMIA

LIFESTYLE THERAPY (Including Medically Assisted Weight Loss)

LIPID PANEL: Assess ASCVD Risk

STATIN THERAPY

If TG >500 mg/dL, fibrates, Rx-grade OM-3 fatty acids, niacin

If statin-intolerant
Try alternate statin, lower statin dose or frequency, or add nonstatin LDL-C-lowering therapies

Repeat lipid panel; assess adequacy, tolerance of therapy

Intensify therapies to attain goals according to risk levels

RISK LEVELS	HIGH	VERY HIGH	EXTREME
	DESIRABLE LEVELS	DESIRABLE LEVELS	DESIRABLE LEVELS
LDL-C (mg/dL)	<100	<70	<55
Non-HDL-C (mg/dL)	<130	<100	<80
TG (mg/dL)	<150	<150	<150
Apo B (mg/dL)	<90	<80	<70

RISK LEVELS:

HIGH*: DM but no other major risk and/or age <40

VERY HIGH*: DM + major ASCVD risk(s) (HTN, Fam Hx, low HDL-C, smoking, CKD3,4)

EXTREME*: DM plus established clinical CVD

If not at desirable levels:
Intensify lifestyle therapy (weight loss, physical activity, dietary changes) and glycemic control; consider additional therapy

To lower LDL-C: Intensify statin, add ezetimibe, PCSK9i, colesevelam, or niacin
To lower Non-HDL-C, TG: Intensify statin and/or add Rx-grade OM3 fatty acid, fibrate, and/or niacin
To lower Apo B, LDL-P: Intensify statin and/or add ezetimibe, PCSK9i, colesevelam, and/or niacin
To lower LDL-C in FH:** Statin + PCSK9i

If TG 135-499: Add icosapent ethyl 4 g/day if high ASCVD risk on maximally tolerated statins

Assess adequacy & tolerance of therapy with focused laboratory evaluations and patient follow-up

* EVEN MORE INTENSIVE THERAPY MIGHT BE WARRANTED   ** FAMILIAL HYPERCHOLESTEROLEMIA

HYPERTENSION

GOAL: SYSTOLIC <130, DIASTOLIC <80 mm Hg

For initial blood pressure >150/100 mm Hg:
DUAL THERAPY

ACEi or ARB

ACEi or ARB +
- Calcium Channel Blocker ✓
- ß-blocker ✓
- Thiazide ✓

If not at goal (2–3 months)
Add calcium channel blocker, ß-blocker or thiazide diuretic

If not at goal (2–3 months)
Add next agent from the above group, repeat

If not at goal (2–3 months)
Additional choices (α-blockers, central agents, vasodilators, aldosterone antagonist)

Achievement of target blood pressure is critical

GLYCEMIC CONTROL ALGORITHM

INDIVIDUALIZE GOALS

A1C ≤6.5% For patients without concurrent serious illness and at low hypoglycemic risk

A1C >6.5% For patients with concurrent serious illness and at risk for hypoglycemia

LIFESTYLE THERAPY AND ONGOING GLUCOSE MONITORING (CGM preferred)

INDEPENDENT OF GLYCEMIC CONTROL, IF ESTABLISHED OR HIGH ASCVD RISK AND/OR CKD, RECOMMEND SGLT2i AND/OR LA GLP1-RA

Entry A1C <7.5%

MONOTHERAPY[1,2]
- ✓ Metformin
- ✓ GLP1-RA
- ✓ SGLT2i
- ✓ DPP4i
- ⚠ TZD
- ✓ AGi
- ⚠ SU/GLN

Independent of glycemic control, if established ASCVD or high risk, CKD 3, or HFrEF, start LA GLP1-RA or SGLT2i with proven efficacy*

MET or other agent

+

DUAL THERAPY[1]
- ✓ GLP1-RA
- ✓ SGLT2i
- ✓ DPP4i
- ⚠ TZD
- ⚠ SU/GLN
- ⚠ Basal Insulin
- ✓ Colesevelam
- ✓ Bromocriptine QR
- ✓ AGi

3 MONTHS[2]

Entry A1C ≥7.5% - 9.0%

TRIPLE THERAPY[1]
- ✓ GLP1-RA
- ✓ SGLT2i
- ⚠ TZD
- ⚠ SU/GLN
- ⚠ Basal Insulin
- ✓ DPP4i
- ✓ Colesevelam
- ✓ Bromocriptine QR
- ✓ AGi

3 MONTHS[2]

Entry A1C >9.0%

SYMPTOMS

NO — DUAL Therapy **OR** TRIPLE Therapy

YES — INSULIN ± Other Agents

ADD OR INTENSIFY INSULIN
Refer to Insulin Algorithm

LEGEND
- ✓ Few adverse events and/or possible benefits
- ⚠ Use with caution

PROGRESSION OF DISEASE

1 Order of medications represents a suggested hierarchy of usage; length of line reflects strength of recommendation
2 If not at goal in 3 months, proceed to next level therapy

*CKD 3: canagliflozin; HFrEF: dapagliflozin
CKD 3 = stage 3 chronic kidney disease; HFrEF = heart failure with reduced ejection fraction; LA = long-acting (≥24 hour duration)

ALGORITHM FOR ADDING/INTENSIFYING INSULIN

START BASAL (Long-Acting Insulin)

A1C <8%
TDD 0.1–0.2 U/kg

A1C >8%
TDD 0.2–0.3 U/kg

Insulin titration every 2–3 days to reach glycemic goal:
- Fixed regimen: Increase TDD by 2 U
- Adjustable regimen:
  - **FBG** >180 mg/dL: add 20% of TDD
  - **FBG** 140–180 mg/dL: add 10% of TDD
  - **FBG** 110–139 mg/dL: add 1 unit
- If hypoglycemia, reduce TDD by:
  - **BG** <70 mg/dL: 10% – 20%
  - **BG** <40 mg/dL: 20% – 40%

Consider discontinuing or reducing sulfonylurea after starting basal insulin (basal analogs preferred to NPH)

*Glycemic Goal:
- <7% for most patients with T2D; fasting and premeal BG <110 mg/dL; absence of hypoglycemia
- A1C and FBG targets may be adjusted based on patient's age, duration of diabetes, presence of comorbidities, diabetic complications, and hypoglycemia risk

Glycemic Control Not at Goal*

INTENSIFY (Prandial Control)

Add GLP1-RA
Or SGLT2i Or DPP4i

Add Prandial Insulin

Basal Plus 1, Plus 2, Plus 3
- Begin prandial insulin before largest meal
- If not at goal, progress to injections before 2 or 3 meals
- **Start: 10% of basal dose or 5 units**

Basal Bolus
- Begin prandial insulin before each meal
- 50% Basal / 50% Prandial TDD 0.3–0.5 U/kg
- **Start: 50% of TDD in three doses before meals**

Insulin titration every 2–3 days to reach glycemic goal:
- Increase prandial dose by 10% or 1-2 units if 2-h postprandial or next premeal glucose consistently >140 mg/dL
- If hypoglycemia, reduce TDD basal and/or prandial insulin by:
  - BG consistently <70 mg/dL: 10% - 20%
  - Severe hypoglycemia (requiring assistance from another person) or BG <40 mg/dL: 20% - 40%

PROFILES OF ANTIHYPERGLYCEMIC MEDICATIONS

	MET	GLP1-RA	SGLT2i	DPP4i	AGi	TZD (moderate dose)	SU / GLN	COLSVL	BCR-QR	INSULIN	PRAML
HYPO	Neutral	Neutral	Neutral	Neutral	Neutral	Neutral	Moderate/Severe (SU) · Mild (GLN)	Neutral	Neutral	Moderate to Severe	Neutral
WEIGHT	Slight Loss	Loss	Loss	Neutral	Neutral	Gain	Gain	Neutral	Neutral	Gain	Loss
RENAL / GU	Contraindicated if eGFR <30 mL/min/1.73 m²	Exenatide Not Indicated CrCl <30 / Potential Benefit of LA GLP1-RA	Not Indicated for eGFR <45 mL/min/1.73 m² / See #1 / Genital Mycotic Infections / Potential CKD Benefit; See #1	Dose Adjustment Necessary (Except Linagliptin) / Effective in Reducing Albuminuria	Neutral	Neutral	More Hypo Risk	Neutral	Neutral	More Hypo Risk	Neutral
GI Sx	Moderate	Moderate	Neutral	Neutral	Moderate	Neutral	Neutral	Mild	Moderate	Neutral	Moderate
CARDIAC — CHF	Neutral	Neutral	Prevent HF Hospitalization Manage HFrEF; See #2	See #4	Neutral	Moderate	Neutral	Neutral	Neutral	CHF Risk	Neutral
CARDIAC — ASCVD	Neutral	Potential Benefit of LA GLP1-RA	See #3	See #4	Neutral	May Reduce Stroke Risk	Possible ASCVD Risk	Lowers LDL-C	Safe	Neutral	Neutral
BONE	Neutral	Neutral	Neutral	Neutral	Neutral	Moderate Fracture Risk	Neutral	Neutral	Neutral	Neutral	Neutral
KETOACIDOSIS	Neutral	Neutral	DKA Can Occur in Various Stress Settings	Neutral	Neutral	Neutral	Neutral	Neutral	Neutral	Neutral	Neutral

Legend:
- Few adverse events or possible benefits
- Use with caution
- Likelihood of adverse effects

1. Canagliflozin indicated for eGFR ≥30 mL/min/1.73 m² in patients with CKD 3 + albuminuria.
2. Dapagliflozin—potential primary prevention of HF hospitalization & demonstrated efficacy in HFrEF.
3. Empagliflozin—FDA approved to reduce CV mortality. Canagliflozin—FDA approved to reduce MACE events.
4. Possible increased hospitalizations for heart failure with alogliptin and saxagliptin.